<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0804257209
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Tremfya
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        GUSELKUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in the refrigerator at a temperature of (2-8) degrees Celsius, keep in the package to protect from light, do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        11118.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Cilag AG, Schaffhausen, Switzerland" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Cilag AG, Schaffhausen, Switzerland
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Janssen Cilag AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tremfya contains the active substance guselkumab which is a type of protein called a monoclonal antibody.</p><p>&nbsp;</p><p>This medicine works by blocking the activity of a protein called IL‑23, which is present at increased levels in people with Crohn&rsquo;s disease and ulcerative colitis.</p><p>&nbsp;</p><p><strong>Crohn&rsquo;s disease </strong></p><p>Tremfya is used to treat adults with moderate to severe Crohn&rsquo;s disease, an inflammatory disease of the bowel. If you have Crohn&rsquo;s disease you will first be given other medicines. If you do not respond well enough or cannot tolerate these medicines, you may be given Tremfya.</p><p>&nbsp;</p><p>Using Tremfya in Crohn&rsquo;s disease can benefit you by reducing the signs and symptoms of the disease such as diarrhoea, abdominal pain, and the inflammation of your intestinal lining. These effects can enable your normal daily activities and reduce fatigue.</p><p>&nbsp;</p><p><strong>Ulcerative colitis </strong></p><p>Tremfya is used to treat adults with moderate to severe ulcerative colitis, an inflammatory disease of the bowel. If you have ulcerative colitis you will first be given other medicines. If you do not respond well enough or cannot tolerate these medicines, you may be given Tremfya.</p><p>&nbsp;</p><p>Using Tremfya in ulcerative colitis can benefit you by reducing the signs and symptoms of the disease including bloody stools, the need to rush to and the number of times you go to the toilet, abdominal pain and the inflammation of your intestinal lining. These effects can improve your ability to do normal daily activities and reduce fatigue.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Tremfya</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to guselkumab or any of the other ingredients of this medicine (listed in section&nbsp;6). If you think you may be allergic, ask your doctor for advice before using Tremfya.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an active infection, including active tuberculosis.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before using Tremfya:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are being treated for an infection;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an infection that does not go away or that keeps coming back;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have tuberculosis or have been in close contact with someone with tuberculosis;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you think you have an infection or have symptoms of an infection (see below under &lsquo;Look out for infections and allergic reactions&rsquo;);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have recently had a vaccination or if you are due to have a vaccination during treatment with Tremfya.</p><p>&nbsp;</p><p>If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before using Tremfya.</p><p>&nbsp;</p><p>As directed by your doctor, you may need blood tests to check if you have high levels of liver enzymes before you start taking Tremfya and when using it. Increases in liver enzymes may occur more frequently in patients receiving Tremfya every 4 weeks than in patients receiving Tremfya every 8 weeks (see &ldquo;How to use Tremfya&rdquo; in section&nbsp;3).</p><p>&nbsp;</p><p><strong>Look out for infections and allergic reactions</strong></p><p>Tremfya can potentially cause serious side effects, including allergic reactions and infections. You must look out for signs of these conditions while you are taking Tremfya.</p><p>&nbsp;</p><p>Signs or symptoms of infections may include fever or flu like symptoms; muscle aches; cough; shortness of breath; burning when you urinate or urinating more often than usual; blood in your phlegm (mucus); weight loss; diarrhoea or stomach pain; warm, red, or painful skin or sores on your body which are different from your psoriasis.</p><p>&nbsp;</p><p>Serious allergic reactions have occurred with Tremfya. Symptoms may include, swollen face, lips, mouth, tongue or throat, difficulty swallowing or breathing, lightheadedness or dizziness, or hives (see &ldquo;Serious side effects&rdquo; in section&nbsp;4).</p><p>&nbsp;</p><p>Stop using Tremfya and tell your doctor or seek medical help <strong>immediately</strong> if you notice any signs indicating a possible serious allergic reaction or an infection.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Tremfya is not recommended for children and adolescents under 18&nbsp;years of age because it has not been studied in this age group.</p><p>&nbsp;</p><p><strong>Other medicines and Tremfya</strong></p><p>Tell your doctor or pharmacist:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are using, have recently used or might use any other medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you recently had or are due to have a vaccination. You should not be given certain types of vaccines (live vaccines) while using Tremfya.</p><p>&nbsp;</p><p><strong>Pregnancy and breast‑feeding</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tremfya should not be used in pregnancy as the effects of this medicine in pregnant women are not known. If you are a woman of childbearing potential, you are advised to avoid becoming pregnant and must use adequate contraception while using Tremfya and for at least 12&nbsp;weeks after the last Tremfya dose. Talk to your doctor if you are pregnant, think you may be pregnant or are planning to have a baby.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor if you are breast‑feeding or are planning to breast‑feed. You and your doctor should decide if you will breast‑feed or use Tremfya.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Tremfya is unlikely to influence your ability to drive and use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How much Tremfya is given and for how long</strong></p><p>Your doctor will decide for how long you need to use Tremfya.</p><p>&nbsp;</p><p><u>Crohn&rsquo;s disease</u></p><p><strong>Treatment start: </strong></p><p>Treatment start can be given either by intravenous infusion or administered subcutaneously:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intravenous infusion: The first dose of Tremfya is 200&nbsp;mg and will be given by your doctor or nurse by intravenous infusion (drip in a vein in your arm). After the first dose, you will receive a second dose 4 weeks later and then a third dose after an additional 4 weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subcutaneous administration: The first dose of Tremfya is 400&nbsp;mg and will be given under the skin (subcutaneous injection) at different locations of the body. After the first dose, you will receive a second dose 4 weeks later and then a third dose after an additional 4 weeks.</p><p><strong>Maintenance therapy:</strong></p><p>A maintenance dose of Tremfya will be given by injection under the skin (subcutaneous injection) either with 100&nbsp;mg or 200&nbsp;mg.&nbsp; Your doctor will decide which maintenance dose you will receive:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A dose of 100&nbsp;mg will be given 8 weeks after the third treatment start dose, and then every 8 weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A dose of 200&nbsp;mg will be given 4 weeks after the third treatment start dose and then every 4 weeks.</p><p>&nbsp;</p><p><u>Ulcerative Colitis</u></p><p><strong>Treatment start:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The first dose of Tremfya is 200&nbsp;mg and will be given by your doctor or nurse by intravenous infusion (drip in a vein in your arm). After the first dose, you will receive a second dose 4&nbsp;weeks later and then a third dose after an additional 4 weeks.</p><p><strong>Maintenance therapy:</strong></p><p>A maintenance dose of Tremfya will be given by injection under the skin (subcutaneous injection) either with 100&nbsp;mg or 200&nbsp;mg. Your doctor will decide which maintenance dose you will receive:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A dose of 100&nbsp;mg will be given 8 weeks after the third treatment start dose, and then every 8&nbsp;weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A dose of 200&nbsp;mg will be given 4 weeks after the third treatment start dose and then every 4&nbsp;weeks.</p><p>&nbsp;</p><p>You may decide together with your doctor to give Tremfya yourself in which case you will get the appropriate training on how to inject Tremfya. Talk to your doctor or nurse if you have any questions about giving yourself an injection. It is important not to try to inject yourself until you have been trained by your doctor or nurse.</p><p>&nbsp;</p><p>For detailed instructions on how to use Tremfya, carefully read the &lsquo;Instructions for use&rsquo; leaflet before use, which is included in the carton.</p><p>&nbsp;</p><p><strong>If you use more Tremfya than you should</strong></p><p>If you have received more Tremfya than you should or the dose has been given sooner than prescribed, inform your doctor.</p><p>&nbsp;</p><p><strong>If you forget to use Tremfya</strong></p><p>If you have forgotten to inject a dose of Tremfya, inform your doctor.</p><p>&nbsp;</p><p><strong>If you stop using Tremfya</strong></p><p>You should not stop using Tremfya without speaking to your doctor first. If you stop treatment, your symptoms may come back.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong><u>Serious side effects</u></strong></p><p>Tell your doctor or seek medical help immediately if you get any of the following side effects:</p><p>&nbsp;</p><p><strong>Possible serious allergic reaction</strong> (may affect up to 1 in 100 people) - the signs or symptoms may include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing or swallowing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, tongue or throat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe itching of the skin, with a red rash or raised bumps</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lightheadedness, low blood pressure, or dizziness</p><p>&nbsp;</p><p><strong><u>Other side effects</u></strong></p><p>The following side effects are all mild to moderate. If any of these side effects becomes severe, tell your doctor, pharmacist or nurse immediately.</p><p>&nbsp;</p><p><strong>Very common</strong> (may affect more than 1&nbsp;in 10&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; respiratory tract infections</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1&nbsp;in 10&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain (arthralgia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of liver enzymes in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1&nbsp;in 100&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased number of a type of white blood cell called neutrophils</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; herpes simplex infections</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fungal infection of the skin, for instance between the toes (e.g., athlete&rsquo;s foot)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach flu (gastroenteritis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness, irritation or pain at the injection site</p><p>&nbsp;</p><p><strong>Rare</strong> (may affect up to 1&nbsp;in 1,000&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the syringe label and on the outer carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Keep the pre‑filled syringe in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C&ndash;8&deg;C). Do not freeze.</p><p>&nbsp;</p><p>Do not shake.</p><p>&nbsp;</p><p>Do not use this medicine if you notice that the medicine is cloudy or discoloured, or contains large particles. Before use, remove the carton from the refrigerator and keep the pre‑filled syringe inside the carton and allow to reach room temperature by waiting for 30&nbsp;minutes.</p><p>&nbsp;</p><p>This medicine is for single use only. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Tremfya contains</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is guselkumab. Each pre‑filled syringe contains 200&nbsp;mg of guselkumab in 2&nbsp;mL solution.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are histidine, histidine monohydrochloride monohydrate, polysorbate 80 (E433), sucrose and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What Tremfya looks like and contents of the pack
	Tremfya is a clear, colourless to light yellow solution for injection (injection). It is available in packs containing one pre-filled syringe and in multipacks comprising 2 cartons, each containing 1 pre-filled syringe. Not all pack sizes may be marketed.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Janssen‑Cilag International NV</p><p>Turnhoutseweg 30</p><p>B‑2340 Beerse</p><p>Belgium</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Cilag AG, Hochstrasse 201 , 8200 Schaffhausen, Switzerland</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>To contact us, go to</strong><strong> </strong><strong>www.janssen.com/contact-us</strong></p><p><strong>&nbsp;</strong></p><p><strong>To Report any side effect (s):</strong></p><p><strong>&nbsp;</strong></p><p><strong>&bull; Saudi Arabia</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&bull; Other GCC states:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&minus; Please contact the relevant competent authority</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Council of Arab Health Ministers</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>THIS IS A MEDICAMENT</strong></p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The doctor and the pharmacist are the experts in medicines, their benefits and risks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not by yourself interrupt the period of treatment prescribed for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not repeat the same prescription without consulting your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep all medicaments out of reach of children.<strong> </strong></p></td></tr></tbody></table><p>&nbsp;</p><p>Council of Arab Health Ministers</p><p>&nbsp;</p><p>Union of Arab Pharmacists</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>This patient information leaflet is approved by Saudi Food and Drug Authority.</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in   26-June-2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي تريمفيا على المادة الفعالة جوسيلكوماب، وهي نوع من البروتين يُسمى الجسم المضاد وحيد النسيلة.</p><p>&nbsp;</p><p dir="RTL">يعمل هذا الدواء عن طريق منع نشاط بروتين يسمى IL-23، والموجود بمستويات متزايدة لدى الأشخاص المصابين &nbsp;بداء كرون أو التهاب القولون التقرحي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>داء &nbsp;كرون </strong></p><p dir="RTL">يُستخدم تريمفيا لعلاج البالغين المصابين بداء &nbsp;كرون المعتدل إلى &nbsp;&nbsp;الشديد ، وهو أحد الأمراض الالتهابية التي تصيب الأمعاء. إذا كنت مصابًا بداء &nbsp;كرون، فستُعطى أدوية أخرى أولاً. إذا لم تستجب جيدًا بما يكفي أو لم تتمكن من تحمل هذه الأدوية، فقد تُعطى تريمفيا.</p><p>&nbsp;</p><p dir="RTL">يمكن أن يفيدك استخدام تريمفيا في علاج داء &nbsp;كرون عن طريق تقليل علامات المرض وأعراضه مثل الإسهال وآلام البطن والتهاب بطانة الأمعاء. تسمح لك هذه التأثيرات بالقيام بالأنشطة اليومية العادية وتقليل التعب.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>التهاب القولون التقرحي </strong></p><p dir="RTL">يُستخدم تريمفيا لعلاج البالغين المصابين بالتهاب القولون التقرحي المعتدل إلى الشديد ، وهو أحد الأمراض الالتهابية التي تصيب الأمعاء. إذا كنت مصابًا بالتهاب القولون التقرحي، فستُعطى أدوية أخرى أولاً. إذا لم تستجب جيدًا بما يكفي أو لم تتمكن من تحمل هذه الأدوية، فقد تُعطى تريمفيا.</p><p>&nbsp;</p><p dir="RTL">يمكن أن يفيدك استخدام تريمفيا في علاج التهاب القولون التقرحي عن طريق تقليل علامات المرض وأعراضه بما في ذلك البراز الدموي، والحاجة الملحة إلى الذهاب إلى الحمام، وعدد مرات استخدام المرحاض، وآلام البطن والتهاب بطانة الأمعاء. يمكن أن تحسن هذه التأثيرات قدرتك على القيام بالأنشطة اليومية العادية وتقليل التعب.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;لا تستخدم &nbsp;تريمفيا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه جوسيلكوماب &nbsp;أو أي من مكونات هذا الدواء الأخرى (المدرجة في القسم&nbsp;6). إذا كنت تعتقد أنك مصاب بالحساسية، فاستشر الطبيب قبل استخدام تريمفيا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بعدوى نشطة، بما في ذلك السل النشط.</p><p>&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">استشر الطبيب أو الصيدلي أو الممرض قبل استخدام تريمفيا إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتلقى علاجًا لعدوى ما</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بعدوى لا تختفي أو &nbsp;&nbsp;تعود باستمرار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بالسل أو كنت مخالطًا عن قرب لشخص مصاب بالسل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعتقد أنك مصاب بعدوى أو تظهر عليك أعراض عدوى (انظر أدناه ضمن عنوان &quot;الانتباه للعدوى وردود الفعل التحسسية&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت قد تلقيت لقاحًا مؤخرًا أو كان من المقرر أن تحصل على لقاح في أثناء تلقي علاج تريمفيا.</p><p>&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا مما إذا كان أي مما سبق ينطبق عليك، فاستشر الطبيب أو الصيدلي أو الممرض قبل استخدام تريمفيا.</p><p>&nbsp;</p><p dir="RTL">وفقًا لتوجيهات الطبيب، قد تحتاج إلى اختبارات دم للتحقق مما إذا كانت لديك مستويات عالية من إنزيمات الكبد قبل البدء في استخدام تريمفيا وعند استخدامه. قد تحدث زيادات في إنزيمات الكبد بشكل متكرر لدى المرضى الذين يتلقون تريمفيا كل 4 أسابيع مقارنة بالمرضى الذين يتلقون تريمفيا كل 8 أسابيع (انظر &quot;كيفية استخدام تريمفيا&quot; في القسم&nbsp;3).</p><p>&nbsp;</p><p dir="RTL"><strong>الانتباه للعدوى وردود الفعل التحسسية</strong></p><p dir="RTL">يُحتمل أن يسبب تريمفيا أعراضًا جانبية خطيرة، منها ردود الفعل التحسسية والعدوى. يجب أن تنتبه لعلامات هذه الحالات في أثناء استخدام تريمفيا.</p><p>&nbsp;</p><p dir="RTL">علامات العدوى أو أعراضها قد تشمل الحمى أو الأعراض الشبيهة بالإنفلونزا أو آلامًا في العضلات أو السعال أو ضيق التنفس أو الشعور بحرقان عند التبول أو التبول أكثر من المعتاد أو وجود دم في البلغم (المخاط) أو فقدان الوزن أو الإسهال أو الشعور بآلام في المعدة أو الشعور بدفء أو احمرار أو ألم في الجلد أو وجود تقرحات تختلف عن الصدفية على جسمك.</p><p>&nbsp;</p><p dir="RTL">صاحبت ردود فعل تحسسية خطرة عند استخدام تريمفيا. قد تشمل الأعراض تورم الوجه أو الشفتين أو الفم أو اللسان أو الحلق أو صعوبة البلع أو التنفس أو الدوار أو الدوخة أو الشرى (انظر &quot;الآثار الجانبية الخطرة&quot; في القسم 4).</p><p>&nbsp;</p><p dir="RTL">توقف عن استخدام تريمفيا وأخبر طبيبك أو اطلب المساعدة الطبية <strong>فورا</strong> إذا لاحظت ظهور أي علامات تشير إلى وجود رد فعل تحسسي خطِر محتمل أو عدوى.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُنصح باستخدام تريمفيا للأطفال والمراهقين تحت سن 18&nbsp;عامًا بسبب عدم إجراء دراسة عليه في هذه الفئة العمرية.</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وتريمفيا</strong></p><p dir="RTL">أخبر الطبيب أو الصيدلي إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتناول أي أدوية أخرى أو تناولتها مؤخرًا أو قد تتناولها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت قد تلقيت لقاحًا مؤخرًا أو من المقرر أن تتلقاه. لا ينبغي أن تُعطى بعض أنواع اللقاحات (اللقاحات الحية) في أثناء استخدام تريمفيا.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي استخدام تريمفيا في أثناء الحمل لأن آثار هذا الدواء في الحوامل غير معروفة. إذا كانت لديكِ القدرة على الإنجاب، فيُنصح بتجنب الحمل ويجب استخدام وسائل منع الحمل المناسبة في أثناء استخدام تريمفيا ولمدة 12&nbsp;أسبوعًا على الأقل بعد آخر علاج من تريمفيا. تحدثي إلى الطبيب إذا كنت حاملاً أو تعتقدين أنكِ حامل أو تخططين لإنجاب طفل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدثي إلى الطبيب إذا كنتِ ترضعين طفلك رضاعة طبيعية أو تخططين للرضاعة الطبيعية. يجب أن تقرري أنتِ والطبيب ما إذا كنتِ ستقومين بالإرضاع طبيعيًا أو ستستخدمين تريمفيا.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المحتمل أن يؤثر تريمفيا في قدرتك على القيادة واستخدام الآلات.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم هذا الدواء دائمًا كما أخبرك الطبيب بالضبط. استشر الطبيب أو الصيدلي إذا لم تكن متأكدًا.</p><p>&nbsp;</p><p dir="RTL"><strong>مقدار جرعة تريمفيا المُعطاة ومدة الاستخدام</strong></p><p dir="RTL">سيقرر الطبيب المدة التي تحتاج إلى استخدام تريمفيا خلالها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>داء &nbsp;كرون</u></strong></p><p dir="RTL"><strong>بدء العلاج: </strong></p><p dir="RTL">يمكن بدء العلاج عن الطريق التسريب بالوريد أو عن طريق الحقن تحت الجلد</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التسريب بالوريد:</p><p dir="RTL">تبلغ الجرعة الأولى من تريمفيا 200&nbsp; مجم تعطى عن طريق الطبيب المعالج او الممرض عن طريق التسريب بالوريد (بالتنقيط فى وريد الذراع) . بعد الجرعة الأولى، ستتلقى جرعة ثانية بعد 4 أسابيع ثم جرعة ثالثة &nbsp;بعد 4 أسابيع إضافية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحقن تحت الجلد:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة الأولى من تريمفيا 400 مجم تعطى عن طريق الحقن تحت الجلد في مواضع مختلفة من الجسم. بعد الجرعة الأولى، ستتلقى جرعة ثانية بعد 4 أسابيع ثم جرعة ثالثة بعد 4 أسابيع إضافية.</p><p dir="RTL"><strong>العلاج بالمداومة:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستُعطى جرعة مداومة من تريمفيا عن طريق الحقن تحت الجلد بمقدار إما 100&nbsp;مجم أو 200&nbsp;مجم. سيقرر طبيبك جرعة المداومة التي ستتلقاها:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستُعطى جرعة بمقدار 100 مجم بعد 8 أسابيع من جرعة بدء العلاج الثالثة، ثم كل 8 أسابيع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستُعطى جرعة بمقدار 200 مجم بعد 4 أسابيع من جرعة بدء العلاج الثالثة، ثم كل 4 أسابيع.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><u>التهاب القولون التقرحي</u></p><p dir="RTL"><strong>بدء العلاج:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الأولى من تريمفيا هي 200&nbsp;مجم وستُعطى من قِبل الطبيب أو الممرض عن طريق التسريب بالوريد (بالتنقيط في وريد &nbsp;الذراع). بعد الجرعة الأولى، ستتلقى جرعة ثانية بعد 4&nbsp;أسابيع ثم جرعة ثالثة بعد 4 أسابيع إضافية.</p><p dir="RTL"><strong>العلاج بالمداومة:</strong></p><p dir="RTL">ستُعطى جرعة مداومة من تريمفيا عن طريق الحقن تحت الجلد بمقدار إما 100&nbsp;مجم أو 200&nbsp;مجم. سيقرر طبيبك جرعة المداومة التي ستتلقاها:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستُعطى جرعة بمقدار 100&nbsp;مجم بعد 8 أسابيع من جرعة بدء العلاج الثالثة، ثم كل 8&nbsp;أسابيع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستُعطى جرعة بمقدار 200&nbsp;مجم بعد 4 أسابيع من جرعة بدء العلاج الثالثة، ثم كل 4&nbsp;أسابيع.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">قد تقرر مع طبيبك أن تتلقى تريمفيا بنفسك وفي هذه الحالة ستحصل على التدريب المناسب حول كيفية حقن تريمفيا. استشر الطبيب أو الممرض إذا كانت لديك أي أسئلة بشأن حقن نفسك. من الضروري أن تتجنب حقن نفسك حتى تتلقى تدريبًا على يد الطبيب أو الممرض.</p><p>&nbsp;</p><p dir="RTL">للحصول على إرشادات مفصلة حول كيفية استخدام تريمفيا، اقرأ بعناية نشرة &quot;تعليمات الاستخدام&quot; قبل الاستخدام، وهي مرفقة في العبوة الكرتونية.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>إذا كنت تستخدم تريمفيا أكثر مما ينبغي</strong></p><p dir="RTL">إذا كنت قد تلقيت تريمفيا أكثر مما ينبغي أو &nbsp;إذا تم إعطاؤك الجرعة في وقت أقرب مما هو موصوف، فأبلغ طبيبك.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا نسيت استخدام تريمفيا</strong></p><p dir="RTL">إذا نسيت حقن جرعة من تريمفيا، فأبلغ طبيبك.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام تريمفيا</strong></p><p dir="RTL">يجب ألا تتوقف عن استخدام تريمفيا من دون التحدث إلى طبيبك أولا. وإذا توقفت عن استخدامه، فقد تعود الأعراض مرة أخرى.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، فاسأل الطبيب أو الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، على الرغم من عدم حدوثها للجميع.</p><p>&nbsp;</p><p dir="RTL"><strong><u>الأعراض الجانبية الخطيرة</u></strong></p><p dir="RTL">استشر طبيبك أو اطلب المساعدة الطبية على الفور إذا ظهرت عليك أي من الآثار الجانبية التالية:</p><p>&nbsp;</p><p dir="RTL"><strong>رد فعل تحسسي خطير محتمل</strong> (قد يؤثر في ما يصل إلى 1 من كل 100 شخص) - قد تشمل العلامات أو الأعراض ما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس أو البلع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه أو الشفتين أو اللسان أو الحلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة شديدة في الجلد، مع طفح جلدي أحمر أو نتوءات مرتفعة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار أو انخفاض ضغط الدم أو الدوخة</p><p>&nbsp;</p><p dir="RTL"><strong><u>الأعراض الجانبية الأخرى</u></strong></p><p dir="RTL">الآثار الجانبية التالية تكون كلها خفيفة إلى معتدلة. &nbsp;. إذا أصبحت أي من هذه الآثار الجانبية شديدة ، فأخبر الطبيب أو الصيدلي أو الممرض على الفور.</p><p>&nbsp;</p><p dir="RTL"><strong>أعراض شائعة جدًا</strong><strong> </strong>( تؤثر على أكثر من شخص<strong> </strong>واحد &nbsp;من كل 10&nbsp;أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات الجهاز التنفسي</p><p>&nbsp;</p><p dir="RTL"><strong>أعراض شائعة</strong><strong> </strong>(قد تؤثر على &nbsp;ما يصل إلى 1&nbsp;من كل 10&nbsp;أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل (ألم مفصلي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى إنزيمات الكبد في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p>&nbsp;</p><p dir="RTL"><strong>أعراض غير شائعة</strong><strong> </strong>&nbsp;قد تؤثر على ما يصل إلى 1&nbsp;من كل 100&nbsp;أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد نوع من &nbsp;أنواع خلايا الدم البيضاء التي تسمى العدلات (نيوتروفيل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الهربس البسيط</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الفطرية للجلد، على سبيل المثال بين أصابع القدم (على سبيل المثال، مرض قدم الرياضي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنفلونزا المعدة (التهاب المعدة والأمعاء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى &nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار أو تهيج أو ألم في موضع الحقن</p><p>&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية النادرة</strong> ( قد تؤثر على ما يصل الى &nbsp;1&nbsp;من كل 1000&nbsp;شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ بالأعراض الجانبية</strong></p><p dir="RTL">إذا ظهرت عليك أي أعراض جانبية، فتحدث إلى الطبيب أو الصيدلي أو الممرض. وذلك ينطبق على أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك المساعدة على توفير مزيد من المعلومات حول سلامة هذا الدواء من خلال الإبلاغ بالأعراض الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى الأطفال وعن متناول أيديهم.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على ملصق المحقنة والعلبة الخارجية بعد الحروف &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p>&nbsp;</p><p dir="RTL">احفظ المحقنة المعبأة &nbsp;مسبقًا في العلبة الخارجية لحماية الدواء من الضوء.</p><p>&nbsp;</p><p dir="RTL">يُحفظ في الثلاجة (2 &ndash; 8 درجات مئوية). &nbsp;يمنع التجميد .</p><p>&nbsp;</p><p dir="RTL">لا ترجَّها.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أنه &nbsp;يبدو ضبابيا أو كان لونه متغيرًا أو يحتوي على جسيمات كبيرة. قبل الاستخدام، أخرج العلبة من الثلاجة وأبق المحقنة المعبأة &nbsp;مسبقًا داخل العلبة واتركها تصل إلى درجة حرارة الغرفة بالانتظار لمدة 30&nbsp;دقيقة.</p><p>&nbsp;</p><p dir="RTL">هذا الدواء مُخصص للاستخدام مرة واحدة فقط. لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مكونات تريمفيا</strong></p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المادة الفعالة جوسيلكوماب. تحتوي كل محقنة معبأة مسبقًا على 200&nbsp;مجم من جوسيلكوماب &nbsp;في محلول 2&nbsp;مل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي هيستيدين، وهيستيدين &nbsp;أحادى هيدروكلوريد أحادى هيدرات ، وبولي سوربات &nbsp;80 (E433)، وسكروز، وماء للحقن.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو تريمفيا ومحتويات العبوة</strong></p><p dir="RTL">تريمفيا محلول شفاف عديم اللون إلى أصفر فاتح مُخصص للحقن (بالمحقنة). ويتوفر في عبوات تحتوي على محقنة واحدة معبأة &nbsp;مسبقًا وفي عبوات متعددة تحتوي على علبتين، في كل منها محقنة واحدة &nbsp;معبأة مسبقًا. ليست كل أحجام العبوات مسوقة .</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق</strong></p><p dir="RTL">جانسن سيلاج إنترناشونال إن فى</p><p dir="RTL">ترنهوتسفيج 30</p><p dir="RTL">بي-2340 بيرس</p><p dir="RTL">بلجيكا</p><p>&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة:</strong></p><p>&nbsp;</p><p dir="RTL">سيلاج ايه جى, هوخستراس 201, 8200 تشافهوزن, سويسرا</p><p dir="RTL">&nbsp;</p><p dir="RTL">للاتصال بنا ، اذهب إلى www.janssen.com/contact-us</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإبلاغ بأي عرض (أعراض) جانبية :</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&bull; المملكة العربية السعودية</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية (NPC):</p><p dir="LTR">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال التابع للهيئة العامة للغذاء والدواء السعودى : 19999</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p><p dir="LTR"><strong>&nbsp;</strong></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="RTL"><strong>&bull; دول مجلس التعاون الخليجي الأخرى:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&minus; يُرجى التواصل مع السلطة المختصة ذات الصلة</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>مجلس وزراء الصحة العرب</strong></p><p>&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td style="vertical-align:top"><p dir="LTR"><strong>&nbsp;</strong></p><p dir="RTL"><strong>هذا دواء</strong></p><p dir="LTR"><strong>&nbsp;</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الدواء هو منتج يؤثر في صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>اتبع بدقة وصفة الطبيب وطريقة الاستخدام وتعليمات الصيدلي الذي صرف لك الدواء.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الطبيب والصيدلي هما الخبيران في الأدوية وفوائدها ومخاطرها.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>لا تكرر الوصفة الطبية نفسها من دون استشارة الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ جميع الأدوية بعيدًا عن متناول الأطفال.<strong> </strong></p><p dir="LTR"><strong>&nbsp;</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">مجلس وزراء الصحة العرب</p><p>&nbsp;</p><p dir="RTL">اتحاد الصيادلة العرب</p><p>&nbsp;</p><p dir="RTL"><strong>تمت الموافقة على هذه النشرة من قبل الهيئة العامة للغذاء والدواء السعودية</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في  26- يونيو- 2024

 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tremfya 200 mg solution for injection in pre-filled syringe
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tremfya 200 mg solution for injection in pre-filled syringe
Each pre filled syringe contains 200 mg of guselkumab in 2 mL solution.

Guselkumab is a fully human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody (mAb) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection)

The solution is clear and colourless to light yellow.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Crohn&rsquo;s disease</u></p><p>&nbsp;</p><p>Tremfya is indicated for the treatment of adult patients with moderately to severely active Crohn&rsquo;s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.</p><p>&nbsp;</p><p><u>Ulcerative colitis</u></p><p>&nbsp;</p><p>Tremfya is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which it is indicated.</p><p>&nbsp;</p><p><u>Posology</u></p><p><em>&nbsp;</em></p><p><em>Crohn&rsquo;s disease</em></p><p><u>Induction:</u></p><p>The recommended induction dose is:</p><p>&middot;&nbsp;&nbsp; 200 mg administered by intravenous infusion at week 0, week 4, and week 8.</p><p>or</p><p>&middot;&nbsp;&nbsp; 400 mg administered by subcutaneous injection at week 0, week 4 and week 8.</p><p><em>For the posology of the 200 mg intravenous infusion induction dosing regimen, </em>see<em> section 4.2 of the Summary of Product Characteristics for Tremfya 200 mg concentrate for solution for infusion. </em></p><p>&nbsp;</p><p><u>Maintenance:</u></p><p>The recommended maintenance dose is 100&nbsp;mg administered by&nbsp;subcutaneous injection at week&nbsp;16 and every 8 weeks (q8w) thereafter after&nbsp;completion of induction dosing.</p><p>&nbsp;</p><p>A dose of 200&nbsp;mg administered by subcutaneous injection at week&nbsp;12 and every 4 weeks (q4w) thereafter may be considered for patients who do not show adequate therapeutic benefit, according to clinical judgement (see section 5.1), after completion of induction dosing.</p><p>&nbsp;</p><p>Immunomodulators and/or corticosteroids may be continued during treatment with guselkumab. In patients who have responded to treatment with guselkumab, corticosteroids may be reduced or discontinued in accordance with standard of care.&nbsp;</p><p>&nbsp;</p><p><em>Ulcerative colitis</em></p><p><u>Induction </u></p><p>The recommended dose is 200&nbsp;mg administered by intravenous infusion at week 0, week 4 and week 8.</p><p>&nbsp;</p><p><em>For the posology of the 200&nbsp;mg intravenous infusion induction dosing regimen, see section 4.2 of the Summary of Product Characteristics for Tremfya 200&nbsp;mg concentrate for solution for infusion. </em></p><p>&nbsp;</p><p><u>Maintenance</u></p><p>The recommended maintenance dose is 100&nbsp;mg administered by&nbsp;subcutaneous injection at week 16 and every 8 weeks (q8w) thereafter after completion of induction dosing.</p><p>&nbsp;</p><p>A dose of 200&nbsp;mg administered by subcutaneous injection at week 12 and every 4 weeks (q4w) thereafter may be considered for patients who do not show adequate therapeutic benefit, according to clinical judgement (see section&nbsp;5.1), after completion of induction dosing.</p><p>&nbsp;</p><p>Immunomodulators and/or corticosteroids may be continued during treatment with guselkumab. In patients who have responded to treatment with guselkumab, corticosteroids may be reduced or discontinued in accordance with standard of care.</p><p>&nbsp;</p><p>Consideration should be given to discontinuing treatment in patients who have shown no evidence of therapeutic benefit after 24&nbsp;weeks of treatment.</p><p>&nbsp;</p><p><u>Missed dose</u></p><p>If a dose is missed, the dose should be administered as soon as possible. Thereafter, dosing should be resumed at the regular scheduled time.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>&nbsp;</em></p><p><em>Elderly </em></p><p>No dose adjustment is required (see section&nbsp;5.2).</p><p>There is limited information in patients aged &ge;&nbsp;65&nbsp;years and very limited information in patients aged &ge;&nbsp;75&nbsp;years (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Renal or hepatic impairment</em></p><p>Tremfya has not been studied in these patient populations. These conditions are generally not expected to have any significant impact on the pharmacokinetics of monoclonal antibodies, and no dose adjustments are considered necessary. For further information on elimination of guselkumab, see section&nbsp;5.2.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Tremfya in children and adolescents below the age of 18&nbsp;years&nbsp;have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Subcutaneous use only. Sites for injection include the abdomen, thigh and back of the upper arm. Do not inject Tremfya into areas where the skin is tender, bruised, red, hard, thick or scaly. If possible, areas of the skin that show psoriasis should be avoided as injection sites.</p><p>&nbsp;</p><p>After proper training in subcutaneous injection technique, patients may inject Tremfya if a physician determines that this is appropriate. However, the physician should ensure appropriate medical follow‑up of patients. Patients should be instructed to inject the full amount of solution according to the &lsquo;Instructions for use&rsquo; provided in the carton.</p><p>For instructions on preparation of the medicinal product before administration, see section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Serious hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Clinically important active infections (e.g. active tuberculosis, see section 4.4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p><u>&nbsp;</u></p><p><u>Infections</u></p><p>&nbsp;</p><p>Guselkumab may increase the risk of infection. Treatment should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.</p><p>&nbsp;</p><p>Patients treated with guselkumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection or is not responding to standard therapy, the patient should be monitored closely and treatment should be discontinued until the infection resolves.</p><p>&nbsp;</p><p><u>Pre‑treatment evaluation for tuberculosis</u></p><p><u>&nbsp;</u></p><p>Prior to initiating treatment, patients should be evaluated for tuberculosis (TB) infection. Patients receiving guselkumab should be monitored for signs and symptoms of active TB during and after treatment. Anti‑TB therapy should be considered prior to initiating treatment in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p><u>&nbsp;</u></p><p>Serious hypersensitivity reactions, including anaphylaxis, have been reported in the post-marketing setting (see section&nbsp;4.8). Some serious hypersensitivity reactions occurred several days after treatment with guselkumab, including cases with urticaria and dyspnoea. If a serious hypersensitivity reaction occurs, administration of guselkumab should be discontinued immediately and appropriate therapy initiated.</p><p>&nbsp;</p><p><u>Hepatic transaminase elevations</u></p><p><u>&nbsp;</u></p><p>In psoriatic arthritis clinical studies, an increased incidence of liver enzyme elevations was observed in patients treated with guselkumab q4w compared to patients treated with guselkumab q8w or placebo (see section&nbsp;4.8).</p><p><em>&nbsp;</em></p><p>When prescribing guselkumab q4w in psoriatic arthritis, it is recommended to evaluate liver enzymes at baseline and thereafter according to routine patient management. If increases in alanine aminotransferase [ALT] or aspartate aminotransferase [AST] are observed and drug-induced liver injury is suspected, treatment should be temporarily interrupted until this diagnosis is excluded.</p><p>&nbsp;</p><p><u>Immunisations</u></p><p><u>&nbsp;</u></p><p>Prior to initiating therapy, completion of all appropriate immunisations should be considered according to current immunisation guidelines. Live vaccines should not be used concurrently in patients treated with guselkumab. No data are available on the response to live or inactive vaccines.</p><p>&nbsp;</p><p>Before live viral or live bacterial vaccination, treatment should be withheld for at least 12&nbsp;weeks after the last dose and can be resumed at least 2&nbsp;weeks after vaccination. Prescribers should consult the Summary of Product Characteristics of the specific vaccine for additional information and guidance on concomitant use of immunosuppressive agents post‑vaccination.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Interactions with CYP450 substrates</u></p><p><u>&nbsp;</u></p><p>In a Phase&nbsp;I study in patients with moderate to severe plaque psoriasis, changes in systemic exposures (C<sub>max</sub> and AUC<sub>inf</sub>) of midazolam, S‑warfarin, omeprazole, dextromethorphan, and caffeine after a single dose of guselkumab were not clinically relevant, indicating that interactions between guselkumab and substrates of various CYP enzymes (CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2) are unlikely. There is no need for dose adjustment when co‑administering guselkumab and CYP450 substrates.</p><p>&nbsp;</p><p><u>Concomitant immunosuppressive therapy or phototherapy</u></p><p><u>&nbsp;</u></p><p>In psoriasis studies, the safety and efficacy of guselkumab in combination with immunosuppressants, including biologics, or phototherapy have not been evaluated. In psoriatic arthritis studies, concomitant MTX use did not appear to influence the safety or efficacy of guselkumab.</p><p>&nbsp;</p><p>In Crohn&rsquo;s disease and ulcerative colitis studies, concomitant use of immunomodulators (eg, azathioprine [AZA]) or corticosteroids did not appear to influence the safety or efficacy of guselkumab.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p><u>&nbsp;</u></p><p>Women of childbearing potential should use effective methods of contraception during treatment and for at least 12&nbsp;weeks after treatment.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no data from the use of guselkumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/foetal development, parturition or postnatal development (see section&nbsp;5.3). As a precautionary measure, it is preferable to avoid the use of Tremfya during pregnancy.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>It is unknown whether guselkumab is excreted in human milk. Human IgGs are known to be excreted in breast milk during the first few days after birth, and decrease to low concentrations soon afterwards; consequently, a risk to the breast-fed infant during this period cannot be excluded. A decision should be made whether to discontinue breast-feeding or to abstain from Tremfya therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. See section&nbsp;5.3 for information on the excretion of guselkumab in animal (cynomolgus monkey) milk.</p><p>&nbsp;</p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>The effect of guselkumab on human fertility has not been evaluated. Animal studies do not indicate direct or indirect harmful effects with respect to fertility (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tremfya has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p>The most common adverse reaction was respiratory tract infections (from approximately 8% of patients in ulcerative colitis studies, 11% of patients in the Crohn&rsquo;s disease studies, and 15% of patients in the psoriasis and psoriatic arthritis clinical studies).</p><p><u>&nbsp;</u></p><p>The overall safety profile in patients treated with Tremfya is similar for patients with psoriasis, psoriatic arthritis, Crohn&rsquo;s disease and and ulcerative colitis.</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>Table&nbsp;1 provides a list of adverse reactions from psoriasis, psoriatic arthritis, Crohn&rsquo;s disease and ulcerative colitis clinical studies as well as adverse reactions reported from post‑marketing experience. The adverse reactions are classified by MedDRA System Organ Class and frequency, using the following convention: very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; List of adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Respiratory tract infections</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Herpes simplex infections</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tinea infections</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Gastroenteritis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaphylaxis</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Arthralgia</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Injection site reactions</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Transaminases increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Neutrophil count decreased</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions </u></p><p><em>&nbsp;</em></p><p><em>Transaminases increased</em></p><p>In two Phase III psoriatic arthritis clinical studies, through the placebo-controlled period, adverse events of increased transaminases (includes ALT increased, AST increased, hepatic enzyme increased, transaminases increased, liver function test abnormal, hypertransaminasaemia) were reported more frequently in the guselkumab-treated groups (8.6% in the 100&nbsp;mg subcutaneous q4w group and 8.3% in the100&nbsp;mg subcutaneous q8w group) than in the placebo group (4.6%). Through 1 year, adverse events of increased transaminases (as above) were reported in 12.9% of patients in the q4w group and 11.7% of patients in the q8w group.</p><p>&nbsp;</p><p>Based on laboratory assessments, most transaminase increases (ALT and AST) were &le;&nbsp;3&nbsp;x upper limit of normal (ULN). Transaminase increases from &gt;&nbsp;3 to &le;&nbsp;5&nbsp;x ULN and &gt;&nbsp;5&nbsp;x ULN were low in frequency, occurring more often in the guselkumab q4w group compared with the guselkumab q8w group (Table&nbsp;2). A similar pattern of frequency by severity and by treatment group was observed through the end of the 2-year Phase III psoriatic arthritis clinical study.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="6" style="vertical-align:top"><p><strong>Table&nbsp;2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequency of patients with transaminase increases post-baseline in two Phase III psoriatic arthritis clinical studies</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Through week 24<sup>a</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Through 1 year<sup>b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p><p>N=370<sup>c</sup></p></td><td style="vertical-align:top"><p>guselkumab</p><p>100&nbsp;mg q8w</p><p>N=373<sup>c</sup></p></td><td style="vertical-align:top"><p>guselkumab</p><p>100&nbsp;mg q4w</p><p>N=371<sup>c</sup></p></td><td style="vertical-align:top"><p>guselkumab</p><p>100&nbsp;mg q8w</p><p>N=373<sup>c</sup></p></td><td style="vertical-align:top"><p>guselkumab</p><p>100&nbsp;mg q4w</p><p>N=371<sup>c</sup></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>ALT</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt;1 to &le;3 x ULN</p></td><td style="vertical-align:top"><p>30.0%</p></td><td style="vertical-align:top"><p>28.2%</p></td><td style="vertical-align:top"><p>35.0%</p></td><td style="vertical-align:top"><p>33.5%</p></td><td style="vertical-align:top"><p>41.2%</p></td></tr><tr><td style="vertical-align:top"><p>&gt;3 to &le; 5 x ULN</p></td><td style="vertical-align:top"><p>1.4%</p></td><td style="vertical-align:top"><p>1.1%</p></td><td style="vertical-align:top"><p>2.7%</p></td><td style="vertical-align:top"><p>1.6%</p></td><td style="vertical-align:top"><p>4.6%</p></td></tr><tr><td style="vertical-align:top"><p>&gt;5 x ULN</p></td><td style="vertical-align:top"><p>0.8%</p></td><td style="vertical-align:top"><p>0.8%</p></td><td style="vertical-align:top"><p>1.1%</p></td><td style="vertical-align:top"><p>1.1%</p></td><td style="vertical-align:top"><p>1.1%</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>AST</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt;1 to &le;3 x ULN</p></td><td style="vertical-align:top"><p>20.0%</p></td><td style="vertical-align:top"><p>18.8%</p></td><td style="vertical-align:top"><p>21.6%</p></td><td style="vertical-align:top"><p>22.8%</p></td><td style="vertical-align:top"><p>27.8%</p></td></tr><tr><td style="vertical-align:top"><p>&gt;3 to &le; 5 x ULN</p></td><td style="vertical-align:top"><p>0.5%</p></td><td style="vertical-align:top"><p>1.6%</p></td><td style="vertical-align:top"><p>1.6%</p></td><td style="vertical-align:top"><p>2.9%</p></td><td style="vertical-align:top"><p>3.8%</p></td></tr><tr><td style="vertical-align:top"><p>&gt;5 x ULN</p></td><td style="vertical-align:top"><p>1.1%</p></td><td style="vertical-align:top"><p>0.5%</p></td><td style="vertical-align:top"><p>1.6%</p></td><td style="vertical-align:top"><p>0.5%</p></td><td style="vertical-align:top"><p>1.6%</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp; placebo-controlled period.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp; patients randomised to placebo at baseline and crossed over to guselkumab are not included.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp; number of patients with at least one post-baseline assessment for the specific laboratory test within the time period.</p></td></tr></tbody></table><p><s>&nbsp;</s></p><p>In the psoriasis clinical studies, through 1 year, the frequency of transaminase increases (ALT and AST) for the guselkumab q8w dose was similar to that observed for the guselkumab q8w dose in the psoriatic arthritis clinical studies. Through 5 years, the incidence of transaminase elevation did not increase by year of guselkumab treatment. Most transaminase increases were &le;&nbsp;3&nbsp;x ULN.</p><p>&nbsp;</p><p>In most cases, the increase in transaminases was transient and did not lead to discontinuation of treatment.</p><p>&nbsp;</p><p>In pooled Phase II and Phase III Crohn&rsquo;s disease clinical studies, through the placebo-controlled period (Week 12), adverse events of increased transaminases (includes ALT increased, AST increased, hepatic enzyme increased, transaminases increased) were reported more frequently in the guselkumab treated groups (1.6% of patients) than in the placebo group (0.6% of patients). Through the reporting period of approximately one year, adverse events of increased transaminases were reported in 2.9% of patients in the guselkumab 200&nbsp;mg subcutaneous q4w treatment group and 2.8% of patients in the guselkumab 100&nbsp;mg subcutaneous q8w treatment group.</p><p>&nbsp;</p><p>Based on laboratory assessments in pooled Phase II and Phase III Crohn&rsquo;s disease clinical studies, the frequency of ALT or AST elevations were lower than those observed in psoriatic arthritis Phase III clinical studies. In pooled Phase II and Phase III Crohn&rsquo;s disease clinical studies, through the placebo-controlled period (Week 12), ALT (&lt;1% of patients) and AST (&lt;1% of patients) elevations &ge;3x ULN were reported in guselkumab treated patients. Through the reporting period of approximately one year, ALT (&lt;2% of patients) and AST (&lt;1.5% of patients) elevations &ge;3x ULN were reported in guselkumab treated patients. In most cases, the increase in transaminases was transient and did not lead to discontinuation of treatment.</p><p><em>&nbsp;</em></p><p><em>Neutrophil count decreased</em></p><p>In two Phase&nbsp;III psoriatic arthritis clinical studies, through the placebo-controlled period, the adverse event of decreased neutrophil count was reported more frequently in the guselkumab-treated group (0.9%) than in the placebo group (0%). Through 1 year, the adverse event of decreased neutrophil count was reported in 0.9% of patients treated with guselkumab. In most cases, the decrease in blood neutrophil count was mild, transient, not associated with infection and did not lead to discontinuation of treatment.</p><p><em>&nbsp;</em></p><p><em>Gastroenteritis </em></p><p>In two Phase&nbsp;III psoriasis clinical studies through the placebo‑controlled period, gastroenteritis occurred more frequently in the guselkumab‑treated group (1.1%) than in the placebo group (0.7%). Through Week&nbsp;264, 5.8% of all guselkumab‑treated patients reported gastroenteritis. Adverse reactions of gastroenteritis were non‑serious and did not lead to discontinuation of guselkumab through Week&nbsp;264. Gastroenteritis rates observed in psoriatic arthritis clinical studies through the placebo-controlled period were similar to those observed in the psoriasis clinical studies.</p><p>&nbsp;</p><p><em>Injection site reactions</em></p><p>In two Phase&nbsp;III psoriasis clinical studies through Week&nbsp;48, 0.7% of guselkumab injections and 0.3% of placebo injections were associated with injection site reactions. Through Week&nbsp;264, 0.4% of guselkumab injections were associated with injection site reactions. Injection site reactions were generally mild to moderate in severity; none were serious, and one led to discontinuation of guselkumab.</p><p>&nbsp;</p><p>In two Phase&nbsp;III psoriatic arthritis clinical studies through Week&nbsp;24, the number of patients that reported 1 or more injection site reactions was low and slightly higher in the guselkumab groups than in the placebo group; 5 (1.3%) patients in the guselkumab q8w group, 4 (1.1%) patients in the guselkumab q4w group, and 1 (0.3%) patient in the placebo group. One patient discontinued guselkumab due to an injection site reaction during the placebo-controlled period of the psoriatic arthritis clinical studies. Through 1 year, the proportion of patients reporting 1 or more injection site reactions was 1.6% and 2.4% in the guselkumab q8w and q4w groups respectively. Overall, the rate of injections associated with injection site reactions observed in psoriatic arthritis clinical studies through the placebo-controlled period was similar to rates observed in the psoriasis clinical studies.</p><p>&nbsp;</p><p>In Phase&nbsp;II and Phase&nbsp;III Crohn&rsquo;s disease clinical studies through Week 48, the proportion of patients that reported 1 or more subcutaneous injection site reactions to guselkumab was 4.1% (0.8% of injections) in the treatment group which received guselkumab 200&nbsp;mg intravenous induction followed by 200&nbsp;mg subcutaneous q4w, and 1.4% (0.6% of injections) of patients in the guselkumab 200&nbsp;mg intravenous induction followed by 100&nbsp;mg subcutaneous q8w group. Overall injection site reactions were mild; none were serious.</p><p>&nbsp;</p><p>In a Phase III Crohn&rsquo;s disease clinical study through Week 24, the proportion of patients that reported 1 or more injection site reactions to guselkumab was 5.2% (0.9% of injections) in the treatment group which received 400&nbsp;mg subcutaneous induction followed by 200 mg subcutaneous q4w and 2.6% (0.5% of injections) of patients in the 400&nbsp;mg guselkumab subcutaneous induction followed by 100&nbsp;mg subcutaneous q8w group. Injection site reactions were mild; none were serious.</p><p>&nbsp;</p><p>In the Phase&nbsp;III ulcerative colitis maintenance clinical study through Week 44, the proportion of patients that reported 1 or more subcutaneous injection site reactions to guselkumab was 7.9% (2.5% of injections) in the guselkumab 200&nbsp;mg subcutaneous q4w group and no injections in the guselkumab 100&nbsp;mg subcutaneous q8w group. Most injection site reactions were mild and none were serious.</p><p>&nbsp;</p><p><em>Immunogenicity</em></p><p>The immunogenicity of guselkumab was evaluated using a sensitive and drug‑tolerant immunoassay.</p><p>&nbsp;</p><p>In pooled Phase&nbsp;II and Phase&nbsp;III analyses in patients with psoriasis and psoriatic arthritis, 5% (n=145) of patients treated with guselkumab developed antidrug antibodies in up to 52&nbsp;weeks of treatment. Of the patients who developed antidrug antibodies, approximately 8% (n=12) had antibodies that were classified as neutralising, which equates to 0.4% of all patients treated with guselkumab. In pooled Phase&nbsp;III analyses in patients with psoriasis, approximately 15% of patients treated with guselkumab developed antidrug antibodies in up to 264&nbsp;weeks of treatment. Of the patients who developed antidrug antibodies, approximately 5% had antibodies that were classified as neutralising, which equates to 0.76% of all patients treated with guselkumab. Antidrug antibodies were not associated with lower efficacy or development of injection‑site reactions.</p><p>&nbsp;</p><p>In pooled Phase II and Phase III analyses up to Week 48 in patients with Crohn&rsquo;s disease who were treated with intravenous induction followed by subcutaneous maintenance dose regimen, approximately 5% (n=30) of patients treated with guselkumab developed antidrug antibodies. Of the patients who developed antidrug antibodies, approximately 7% (n=2) had antibodies that were classified as neutralising antibodies, which equates to 0.3% of guselkumab treated patients.</p><p>In a Phase III analysis up to Week 24 in patients with Crohn&rsquo;s disease who were treated with subcutaneous induction followed by subcutaneous maintenance dose regimen, approximately 3% (n=8) of patients treated with guselkumab developed antidrug antibodies. Of the patients, none had antibodies that were classified as neutralising antibodies. Antidrug antibodies were not associated with lower efficacy or development of injection site reactions.</p><p>&nbsp;</p><p>In pooled Phase&nbsp;II and Phase&nbsp;III analyses in patients with ulcerative colitis, approximately 12% (n=58) of patients treated with guselkumab for up to 56&nbsp;weeks developed antidrug antibodies. Of the patients who developed antidrug antibodies, approximately 16% (n=9) had antibodies that were classified as neutralising, which equates to 2% of all patients treated with guselkumab. Antidrug antibodies were not associated with lower efficacy or the development of injection-site reactions.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p>&nbsp;</p><p><strong>To Report any side effect (s):</strong></p><p><strong>&nbsp;</strong></p><p><strong>&bull; Saudi Arabia</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&bull; Other GCC states:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&minus; Please contact the relevant competent authority</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single intravenous doses of guselkumab up to 987&nbsp;mg (10&nbsp;mg/kg) have been administered in healthy volunteers and single subcutaneous doses of guselkumab up to 300&nbsp;mg have been administered in patients with plaque psoriasis in clinical studies without dose‑limiting toxicity. In the event of overdose, the patient must be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment must be administered immediately.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, interleukin inhibitors, ATC code: L04AC16.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Guselkumab is a human IgG1&lambda; monoclonal antibody (mAb) that binds selectively to the interleukin&nbsp;23 (IL‑23) protein with high specificity and affinity through the antigen binding site. IL-23 is a cytokine that is involved in inflammatory and immune responses. By blocking IL-23 from binding to its receptor, guselkumab inhibits IL-23-dependent cell signalling and release of proinflammatory cytokines.</p><p>&nbsp;</p><p>Levels of IL‑23 are elevated in the skin of patients with plaque psoriasis. In patients with Crohn&rsquo;s disease and<strong> </strong>ulcerative colitis, levels of IL-23 are elevated in the colon tissue. In <em>in&nbsp;vitro</em> models, guselkumab was shown to inhibit the bioactivity of IL‑23 by blocking its interaction with cell surface IL‑23 receptor, disrupting IL‑23‑mediated signalling, activation and cytokine cascades. Guselkumab exerts clinical effects in plaque psoriasis, psoriatic arthritis, Crohn&rsquo;s disease and ulcerative colitis through blockade of the IL‑23 cytokine pathway.</p><p>&nbsp;</p><p>Myeloid cells expressing Fc-gamma receptor 1 (CD64) have been shown to be a predominant source of IL-23 in inflamed tissue in psoriasis, Crohn&rsquo;s disease and ulcerative colitis. Guselkumab has demonstrated <em>in vitro</em> blocking of IL-23 and binding to CD64. These results indicate that guselkumab is able to neutralize IL-23 at the cellular source of inflammation.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>In a Phase&nbsp;I study, treatment with guselkumab resulted in reduced expression of IL‑23/Th17 pathway genes and psoriasis‑associated gene expression profiles, as shown by analyses of mRNA obtained from lesional skin biopsies of patients with plaque psoriasis at Week&nbsp;12 compared to baseline. In the same Phase&nbsp;I study, treatment with guselkumab resulted in improvement of histological measures of psoriasis at Week&nbsp;12, including reductions in epidermal thickness and T‑cell density. In addition, reduced serum IL‑17A, IL‑17F and IL‑22 levels compared to placebo were observed in guselkumab treated patients in Phase&nbsp;II and Phase&nbsp;III plaque psoriasis studies. These results are consistent with the clinical benefit observed with guselkumab treatment in plaque psoriasis.</p><p>&nbsp;</p><p>In psoriatic arthritis patients in Phase&nbsp;III studies, serum levels of acute phase proteins C-reactive protein, serum amyloid A, and IL-6, and Th17 effector cytokines IL-17A, IL-17F and IL-22 were elevated at baseline. Guselkumab decreased the levels of these proteins within 4&nbsp;weeks of initiation of treatment. Guselkumab further reduced the levels of these proteins by Week&nbsp;24 compared to baseline and also to placebo.</p><p>&nbsp;</p><p>In patients with Crohn&rsquo;s disease and ulcerative colitis, guselkumab treatment led to decreases in inflammatory markers including C-reactive protein (CRP) and fecal calprotectin through induction Week 12, which were sustained through one year of maintenance treatment. Serum protein levels of IL-17A, IL-22 and IFN&gamma; were reduced as early as Week 4, and continued to decrease through induction Week 12. Guselkumab also reduced colon mucosal biopsy RNA levels of IL-17A, IL-22 and IFN&gamma; at Week 12.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><u>&nbsp;</u></p><p><em><u>Crohn&rsquo;s Disease </u></em></p><p>&nbsp;</p><p>The efficacy and safety of guselkumab were evaluated in three Phase III clinical studies in adult patients with moderately to severely active Crohn&rsquo;s disease who had an inadequate response, loss of response or intolerance to either oral corticosteroids, conventional immunomodulators (AZA, 6-MP, MTX) and/or biologic therapy (TNF blocker or vedolizumab): two identically designed 48-week multicentre, randomised, double-blind, placebo- and active-controlled (ustekinumab), parallel group studies (GALAXI 2 and GALAXI 3) and one 24-week multicentre, randomised, double-blind, placebo-controlled, parallel group study (GRAVITI). All three studies had a treat-through study design: patients randomised to guselkumab (or ustekinumab for GALAXI 2 and GALAXI 3) maintained that treatment assignment for the duration of the study.</p><p>&nbsp;</p><p><em>GALAXI 2 and GALAXI 3</em></p><p>In the Phase III studies GALAXI 2 and GALAXI 3, moderately to severely active Crohn&rsquo;s disease was defined as a Crohn&rsquo;s Disease Activity Index [CDAI] score of &ge; 220 and &le; 450 and a Simple Endoscopic Score for CD (SES-CD) of &ge;6 (or &ge;4 for patients with isolated ileal disease). Additional criteria for GALAXI 2/3 included a mean daily stool frequency (SF) &gt;3 or mean daily abdominal pain score (AP) &gt;1.</p><p>&nbsp;</p><p>In GALAXI 2 and GALAXI 3 studies, patients were randomised in a 2:2:2:1 ratio to receive guselkumab 200&nbsp;mg intravenous induction at Weeks&nbsp;0, 4 and 8 followed by guselkumab 200&nbsp;mg subcutaneous q4w maintenance; or guselkumab 200&nbsp;mg intravenous induction at Weeks&nbsp;0, 4 and 8, followed by guselkumab 100&nbsp;mg subcutaneous q8w maintenance; or ustekinumab approximately 6&nbsp;mg/kg intravenous induction at Week&nbsp;0 followed by ustekinumab 90&nbsp;mg subcutaneous q8w maintenance; or placebo. Placebo non-responders received ustekinumab starting at Week&nbsp;12.</p><p>&nbsp;</p><p>A total of 1021 patients were evaluated in GALAXI 2 (n=508) and GALAXI 3 (n=513). The median age was 34 years (ranging from 18 to 83 years), 57.6% were male; and 74.3% identified as White, 21.3% as Asian and 1.5% as Black.</p><p>&nbsp;</p><p>In GALAXI 2, 52.8% of patients had previously failed treatment with at least one biologic therapy, 41.9% were biologic na&iuml;ve, and 5.3% had previously received but had not failed a biologic. At baseline, 37.4% of the patients were receiving oral corticosteroids and 29.9% of the patients were receiving conventional immunomodulators.</p><p>&nbsp;</p><p>In GALAXI 3, 51.9% of patients had previously failed treatment with at least one biologic therapy, 41.5% were biologic na&iuml;ve, and 6.6% had previously received but had not failed a biologic. At baseline, 36.1% of the patients were receiving oral corticosteroids and 30.2% of the patients were receiving conventional immunomodulators.</p><p>&nbsp;</p><p>In GALAXI 2 and GALAXI 3, a significantly greater proportion of patients achieved the co-primary efficacy endpoints of clinical remission at Week 12 and endoscopic response at Week 12 in the guselkumab treated group compared to placebo (Table 3). A significantly greater proportion of patients in the guselkumab treated group achieved PRO-2 remission and fatigue response, and a greater proportion of patients achieved endoscopic remission, all at Week 12, compared with the placebo treatment group (Table 4).</p><p>&nbsp;</p><p>Table&nbsp;3:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proportion of patients meeting co-primary efficacy endpoints with guselkumab versus placebo at Week 12 in GALAXI 2 and GALAXI 3</p><table border="0" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>GALAXI 2</p></td><td colspan="2" style="vertical-align:top"><p>GALAXI 3</p></td></tr><tr><td colspan="2" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=76)</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Guselkumab intravenous induction</strong><sup>a</sup></p><p><strong>(N=289)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=72)</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Guselkumab intravenous induction</strong><sup>a</sup></p><p><strong>(N=</strong><strong>293</strong><strong>)</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Clinical remission at Week 12<sup>b</sup></strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>17 (22%)</p></td><td style="vertical-align:top"><p>136 (47%)<sup> f</sup></p></td><td style="vertical-align:top"><p>11 (15%)<sup> </sup></p></td><td style="vertical-align:top"><p>138 (47%)<sup>f</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Biologic na&iuml;ve<sup>c</sup></p></td><td style="vertical-align:top"><p>6/34 (18%)</p></td><td style="vertical-align:top"><p>60/121 (50%)</p></td><td style="vertical-align:top"><p>4/27 (15%)</p></td><td style="vertical-align:top"><p>61/123 (50%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Prior biologic failure<sup>d</sup></p></td><td style="vertical-align:top"><p>9/39 (23%)</p></td><td style="vertical-align:top"><p>67/150 (45%)</p></td><td style="vertical-align:top"><p>6/39 (15%)</p></td><td style="vertical-align:top"><p>71/150 (47%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Endoscopic response at Week 12<sup>e</sup></strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>8 (11%)<sup> </sup></p></td><td style="vertical-align:top"><p>109 (38%)<sup> f</sup></p></td><td style="vertical-align:top"><p>10 (14%)<sup> </sup></p></td><td style="vertical-align:top"><p>106 (36%)<sup>f</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Biologic na&iuml;ve<sup>c</sup></p></td><td style="vertical-align:top"><p>5/34 (15%)</p></td><td style="vertical-align:top"><p>62/121 (51%)</p></td><td style="vertical-align:top"><p>6/27 (22%)</p></td><td style="vertical-align:top"><p>51/123 (41%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Prior biologic failure<sup>d</sup></p></td><td style="vertical-align:top"><p>2/39 (5%)</p></td><td style="vertical-align:top"><p>40/150 (27%)</p></td><td style="vertical-align:top"><p>3/39 (8%)</p></td><td style="vertical-align:top"><p>47/150 (31%)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; Guselkumab 200&nbsp;mg intravenous induction at Week 0, Week 4 and Week 8 &ndash; Two guselkumab treatment groups were combined for this column as patients received the same intravenous dose regimen prior to Week 12.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp; Clinical remission is defined as CDAI score &lt;150.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp; An additional 9 patients in the placebo group and 38 patients in the guselkumab 200&nbsp;mg intravenous group were previously exposed to but did not fail a biological therapy.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp; Includes inadequate response, loss of response, or intolerance to biologic therapy (TNF blockers or vedolizumab) for Crohn&rsquo;s disease.</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp; Endoscopic response is defined as &ge; 50% improvement from baseline in SES-CD score or SES-CD Score &le; 2.</p><p><sup>f</sup>&nbsp;&nbsp;&nbsp;&nbsp; p &lt; 0.001</p><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="6" style="vertical-align:top"><p>&nbsp;</p><p>Table&nbsp;4:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proportion of patients meeting short-term major secondary efficacy endpoints with guselkumab versus placebo at Week 12 in GALAXI 2 and GALAXI 3</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>GALAXI 2</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>GALAXI 3</strong></p></td></tr><tr><td colspan="2" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=76)</strong></p></td><td style="vertical-align:top"><p><strong>Guselkumab intravenous induction</strong><strong><sup>a </sup></strong></p><p><strong>(N=289)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=72)</strong></p></td><td style="vertical-align:top"><p><strong>Guselkumab intravenous induction</strong><strong><sup>a </sup></strong><strong>(N=</strong><strong>293</strong><strong>)</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>PRO-2 remission</strong><strong><sup>b</sup></strong><strong> at Week 12</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>16 (21%)</p></td><td style="vertical-align:top"><p>124 (43%)<sup>g</sup></p></td><td style="vertical-align:top"><p>10 (14%)</p></td><td style="vertical-align:top"><p>122 (42%)<sup>g</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Biologic na&iuml;ve<sup>c</sup></p></td><td style="vertical-align:top"><p>8/34 (24%)</p></td><td style="vertical-align:top"><p>52/121 (43%)</p></td><td style="vertical-align:top"><p>4/27 (15%)</p></td><td style="vertical-align:top"><p>58/123 (47%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Prior biologic failure<sup>d</sup></p></td><td style="vertical-align:top"><p>5/39 (13%)</p></td><td style="vertical-align:top"><p>61/150 (41%)</p></td><td style="vertical-align:top"><p>5/39 (13%)</p></td><td style="vertical-align:top"><p>59/150 (39%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Fatigue response</strong><strong><sup>e</sup></strong><strong> at Week 12</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>22 (29%)</p></td><td style="vertical-align:top"><p>131 (45%)<sup>h</sup></p></td><td style="vertical-align:top"><p>13 (18%)</p></td><td style="vertical-align:top"><p>127 (43%)<sup>g</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Biologic na&iuml;ve<sup>c</sup></p></td><td style="vertical-align:top"><p>11/34 (32%)</p></td><td style="vertical-align:top"><p>58/121 (48%)</p></td><td style="vertical-align:top"><p>5/27 (19%)</p></td><td style="vertical-align:top"><p>56/123 (46%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Prior biologic failure<sup>d</sup></p></td><td style="vertical-align:top"><p>10/39 (26%)</p></td><td style="vertical-align:top"><p>62/150 (41%)</p></td><td style="vertical-align:top"><p>7/39 (18%)</p></td><td style="vertical-align:top"><p>64/150 (43%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Endoscopic remission</strong><strong><sup>f</sup></strong><strong> at Week 12</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>1 (1%)</p></td><td style="vertical-align:top"><p>43 (15%)<sup> </sup></p></td><td style="vertical-align:top"><p>6 (8%)</p></td><td style="vertical-align:top"><p>47 (16%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Biologic na&iuml;ve<sup>c</sup></p></td><td style="vertical-align:top"><p>1/34 (3%)</p></td><td style="vertical-align:top"><p>27/121 (22%)</p></td><td style="vertical-align:top"><p>5/27 (19%)</p></td><td style="vertical-align:top"><p>31/123 (25%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Prior biologic failure<sup>d</sup></p></td><td style="vertical-align:top"><p>0/39</p></td><td style="vertical-align:top"><p>13/150 (9%)</p></td><td style="vertical-align:top"><p>0/39</p></td><td style="vertical-align:top"><p>14/150 (9%)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; Guselkumab 200&nbsp;mg intravenous induction at Week 0, Week 4 and Week 8 &ndash; Two guselkumab treatment groups were combined for this column as they received the same intravenous dose regimen.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp; PRO-2 remission is defined as AP mean daily score at or below 1 and SF mean daily score at or below 3, and no worsening of AP or SF from baseline.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp; An additional 9 patients in the placebo group and 38 patients in the guselkumab 200&nbsp;mg intravenous group, were previously exposed to but did not fail a biological therapy.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp; Includes inadequate response, loss of response, or intolerance to biologic therapy (TNF blockers or vedolizumab) for Crohn&rsquo;s disease.</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp; Fatigue response is defined as improvement of &ge; 7 points in PROMIS Fatigue Short Form 7a.</p><p><sup>f</sup>&nbsp;&nbsp;&nbsp;&nbsp; Endoscopic remission is defined as SES-CD Score &le; 2.</p><p><sup>g</sup>&nbsp;&nbsp;&nbsp; p &lt; 0.001</p><p><sup>h</sup>&nbsp;&nbsp;&nbsp; p &lt; 0.05</p><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>In GALAXI 2 and GALAXI 3, a significantly greater proportion of patients were in corticosteroid-free clinical remission at Week 48 and endoscopic response at Week 48 in the guselkumab treated group compared to placebo (Table 5).</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:103%"><tbody><tr><td colspan="7" style="vertical-align:top"><p>Table&nbsp;5:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proportion of patients meeting long-term efficacy endpoints with guselkumab versus placebo at Week 48 in GALAXI 2 and GALAXI 3</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>GALAXI 2</p></td><td colspan="3" style="vertical-align:top"><p>GALAXI 3</p></td></tr><tr><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=76)</strong></p></td><td style="vertical-align:top"><p><strong>Guselkumab intravenous induction&rarr; 100&nbsp;mg q8w</strong></p><p><strong>subcutaneous injection<sup>a</sup></strong></p><p><strong>(N=143</strong><strong>)</strong></p></td><td style="vertical-align:top"><p><strong>Guselkumab intravenous induction&rarr; 200&nbsp;mg q4w</strong></p><p><strong>subcutaneous injection<sup>b</sup></strong></p><p><strong>(N=146</strong><strong>)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=</strong><strong>72</strong><strong>)</strong></p></td><td style="vertical-align:top"><p><strong>Guselkumab intravenous induction&rarr; 100&nbsp;mg q8w</strong></p><p><strong>subcutaneous injection<sup>a</sup></strong></p><p><strong>(N=</strong><strong>143</strong><strong>)</strong></p></td><td style="vertical-align:top"><p><strong>Guselkumab intravenous induction&rarr; 200&nbsp;mg q4w</strong></p><p><strong>subcutaneous injection<sup>b</sup></strong></p><p><strong>(N=</strong><strong>150</strong><strong>)</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Corticosteroid-free clinical remission<sup>c</sup> at Week 48</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>9 (12%)</p></td><td style="vertical-align:top"><p>65 (45%)<sup>g</sup></p></td><td style="vertical-align:top"><p>75 (51%)<sup> g</sup></p></td><td style="vertical-align:top"><p>10 (14%)</p></td><td style="vertical-align:top"><p>63 (44%)<sup>g</sup></p></td><td style="vertical-align:top"><p>72 (48%)<sup> g</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic na&iuml;ve<sup>d</sup></p></td><td style="vertical-align:top"><p>2/34 (6%)</p></td><td style="vertical-align:top"><p>32/58 (55%)</p></td><td style="vertical-align:top"><p>33/63 (52%)</p></td><td style="vertical-align:top"><p>5/27 (19%)</p></td><td style="vertical-align:top"><p>25/58 (43%)</p></td><td style="vertical-align:top"><p>32/65 (49%)</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic failure<sup>e</sup></p></td><td style="vertical-align:top"><p>5/39 (13%)</p></td><td style="vertical-align:top"><p>28/77 (36%)</p></td><td style="vertical-align:top"><p>37/73 (51%)</p></td><td style="vertical-align:top"><p>5/39 (13%)</p></td><td style="vertical-align:top"><p>37/76 (49%)</p></td><td style="vertical-align:top"><p>36/74 (49%)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Endoscopic response</strong><strong><sup>f</sup> at Week 48</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>5 (7%)</p></td><td style="vertical-align:top"><p>55 (38 %)<sup>g</sup></p></td><td style="vertical-align:top"><p>56 (38%)<sup>g</sup></p></td><td style="vertical-align:top"><p>4 (6%)</p></td><td style="vertical-align:top"><p>47 (33%)<sup>g</sup></p></td><td style="vertical-align:top"><p>54 (36%)<sup> g</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic na&iuml;ve<sup>d</sup></p></td><td style="vertical-align:top"><p>2/34 (6%)</p></td><td style="vertical-align:top"><p>26/58 (45%)</p></td><td style="vertical-align:top"><p>30/63 (48%)</p></td><td style="vertical-align:top"><p>2/27 (7%)</p></td><td style="vertical-align:top"><p>22/58 (38%)</p></td><td style="vertical-align:top"><p>25/65 (38%)</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic failure<sup>e</sup></p></td><td style="vertical-align:top"><p>3/39 (8%)</p></td><td style="vertical-align:top"><p>27/77 (35%)</p></td><td style="vertical-align:top"><p>20/73 (27%)</p></td><td style="vertical-align:top"><p>2/39 (5%)</p></td><td style="vertical-align:top"><p>25/76 (33%)</p></td><td style="vertical-align:top"><p>27/74 (36%)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guselkumab 200&nbsp;mg intravenous induction at Week 0, Week 4 and Week 8 followed by guselkumab 100&nbsp;mg subcutaneous q8w thereafter for up to 48 weeks.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guselkumab 200&nbsp;mg intravenous induction at Week 0, Week 4 and Week 8 followed by guselkumab 200&nbsp;mg subcutaneous q4w thereafter for up to 48 weeks.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroid-free clinical remission is defined as CDAI score &lt;150 at Week 48 and not receiving corticosteroids at Week 48.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp; An additional 9 patients in the placebo group and 21 patients in the guselkumab 200&nbsp;mg subcutaneous q4w group, and 17 patients in the guselkumab 100&nbsp;mg subcutaneous q8w group, were previously exposed to but did not fail a biological therapy.</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp; Includes inadequate response, loss of response, or intolerance to biologic therapy (TNF blockers or vedolizumab) for Crohn&rsquo;s disease.</p><p><sup>f</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Endoscopic response is defined as &ge; 50% improvement from baseline in SES-CD score or SES-CD Score &le; 2.</p><p><sup>g</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p &lt; 0.001</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Results of the long-term efficacy endpoints with both guselkumab maintenance dose regimens compared to ustekinumab at Week 48 are presented below (Table 6). The results were consistent across GALAXI 2 and GALAXI 3.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:112%"><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>Table&nbsp;6:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proportion of patients meeting long term efficacy endpoints with guselkumab versus ustekinumab at Week 48 in GALAXI 2 and GALAXI 3</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>GALAXI 2</p></td><td colspan="3" style="vertical-align:top"><p>GALAXI 3</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Ustekinumab 6&nbsp;mg/kg </strong><strong>intravenous induction</strong><strong> </strong><strong>&rarr; </strong><strong>90</strong><strong>&nbsp;</strong><strong>mg </strong><strong>q8w</strong></p><p><strong>subcutaneous injection<sup>a</sup></strong></p><p><strong>(N=143) </strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Guselkumab intravenous induction&rarr; 100&nbsp;mg </strong></p><p><strong>q8w</strong></p><p><strong>subcutaneous injection<sup>b</sup></strong></p><p><strong>(N=143</strong><strong>)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Guselkumab intravenous induction &rarr; </strong></p><p><strong>200&nbsp;mg q4w</strong></p><p><strong>subcutaneous injection<sup>c</sup></strong></p><p><strong>(N=146</strong><strong>)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Ustekinumab 6 mg/kg </strong><strong>intravenous induction &rarr;</strong><strong> 90</strong><strong>&nbsp;</strong><strong>mg </strong><strong>q8w</strong></p><p><strong>subcutaneous injection<sup>a</sup></strong></p><p><strong>(N=148)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Guselkumab intravenous induction&rarr; 100&nbsp;mg </strong></p><p><strong>q8w</strong></p><p><strong>subcutaneous injection<sup>b</sup></strong></p><p><strong>(N=143</strong><strong>)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Guselkumab intravenous induction &rarr; </strong></p><p><strong>200&nbsp;mg q4w</strong></p><p><strong>subcutaneous injection<sup>c</sup></strong></p><p><strong>(N=150</strong><strong>)</strong></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Clinical remission at Week 48 and endoscopic response<sup>d</sup> at Week 48</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>56 (39%)</p></td><td style="vertical-align:top"><p>60 (42%)<sup> </sup></p></td><td style="vertical-align:top"><p>72 (49%)</p></td><td style="vertical-align:top"><p>42 (28%)</p></td><td style="vertical-align:top"><p>59 (41%)<sup>k </sup></p></td><td style="vertical-align:top"><p>68 (45%)<sup> k </sup></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Endoscopic response<sup>e </sup></strong><strong>at Week 48</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td rowspan="2" style="vertical-align:top"><p>60 (42%)</p></td><td rowspan="2" style="vertical-align:top"><p>70 (49%)</p></td><td rowspan="2" style="vertical-align:top"><p>82 (56%)<sup> </sup></p></td><td style="vertical-align:top"><p>48 (32%)</p></td><td style="vertical-align:top"><p>67 (47%)</p></td><td style="vertical-align:top"><p>74 (49%)<sup> </sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Endoscopic remission<sup>f</sup> </strong><strong>at Week 48</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>29 (20%)</p></td><td style="vertical-align:top"><p>38 (27%)</p></td><td style="vertical-align:top"><p>35 (24%)</p></td><td style="vertical-align:top"><p>19 (13%)</p></td><td style="vertical-align:top"><p>34 (24%)<sup>k </sup></p></td><td style="vertical-align:top"><p>28 (19%)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Clinical remission<sup>g </sup>at Week 48</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>93 (65%)</p></td><td style="vertical-align:top"><p>92 (64%)</p></td><td style="vertical-align:top"><p>109 (75%)</p></td><td style="vertical-align:top"><p>90 (61%)</p></td><td style="vertical-align:top"><p>95 (66%)</p></td><td style="vertical-align:top"><p>99 (66%)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Corticosteroid-free clinical remission<sup>h </sup></strong><strong>at Week 48</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>87 (61%)</p></td><td style="vertical-align:top"><p>90 (63%)</p></td><td style="vertical-align:top"><p>104 (71%)</p></td><td style="vertical-align:top"><p>87 (59%)</p></td><td style="vertical-align:top"><p>92 (64%)</p></td><td style="vertical-align:top"><p>96 (64%)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Durable clinical remission<sup>i </sup></strong><strong>at Week 48</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>64 (45%)</p></td><td style="vertical-align:top"><p>66 (46%)</p></td><td style="vertical-align:top"><p>76 (52%)</p></td><td style="vertical-align:top"><p>58 (39%)</p></td><td style="vertical-align:top"><p>72 (50%)</p></td><td style="vertical-align:top"><p>73 (49%)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>PRO-2 remission<sup>j </sup></strong><strong>at Week 48</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>85 (59%)</p></td><td style="vertical-align:top"><p>86 (60%)</p></td><td style="vertical-align:top"><p>101 (69%)</p></td><td style="vertical-align:top"><p>78 (53%)</p></td><td style="vertical-align:top"><p>83 (58%)</p></td><td style="vertical-align:top"><p>84 (56%)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ustekinumab 6&nbsp;mg/kg intravenous induction at Week 0 followed by ustekinumab 90&nbsp;mg subcutaneous q8w thereafter for up to 48 weeks.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guselkumab 200&nbsp;mg intravenous induction at Week 0, Week 4 and Week 8 followed by guselkumab 100&nbsp;mg subcutaneous q8wthereafter for up to 48 weeks.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guselkumab 200&nbsp;mg intravenous induction at Week 0, Week 4 and Week 8 followed by guselkumab 200&nbsp;mg subcutaneous q4w thereafter for up to 48 weeks.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A combination of clinical remission and endoscopic response as defined below.</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Endoscopic response is defined as &ge; 50% improvement from baseline in SES-CD score or SES-CD Score &le; 2.</p><p><sup>f</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Endoscopic remission is defined as SES-CD Score &le; 2.</p><p><sup>g</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical remission is defined as CDAI score &lt;150.</p><p><sup>h</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroid-free clinical remission is defined as CDAI score &lt;150 at Week 48 and not receiving corticosteroids at Week 48.</p><p><sup>i</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Durable clinical remission is defined as CDAI &lt; 150 for &ge;80% of all visits between Week 12 and Week 48 (at least 8 of 10 visits), which must include Week 48.</p><p><sup>j</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PRO-2 remission is defined as AP mean daily score at or below 1 and SF mean daily score at or below 3, and no worsening of AP or SF from baseline.</p><p><sup>k</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p &lt; 0.05<sup>12</sup></p></td></tr></tbody></table><p>&nbsp;</p><p>Results of the long-term efficacy endpoints with both guselkumab maintenance dose regimens compared to ustekinumab at Week 48 in the pooled GALAXI 2 and GALAXI 3 studies including biologic na&iuml;ve and prior biologic failure subpopulations are presented below in Table 7</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:104%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table&nbsp;7:</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Proportion of patients meeting long term efficacy endpoints with guselkumab versus ustekinumab at Week 48 in pooled GALAXI 2 and GALAXI 3 </strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Pooled GALAXI 2 &amp; GALAXI 3</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p><strong>Ustekinumab 6&nbsp;mg/kg intravenous induction &rarr; 90&nbsp;mg q8w subcutaneous injectiona</strong></p><p><strong>(N=291)</strong></p></td><td style="vertical-align:top"><p><strong>Guselkumab intravenous induction &rarr; 100&nbsp;mg</strong></p><p><strong>q8w</strong></p><p><strong>subcutaneous injection<sup>b</sup></strong></p><p><strong>(N=</strong><strong>286</strong><strong>)</strong></p></td><td style="vertical-align:top"><p><strong>Guselkumab intravenous induction &rarr; </strong></p><p><strong>200&nbsp;mg q4w</strong></p><p><strong>subcutaneous injection<sup>c</sup></strong></p><p><strong>(N=</strong><strong>296</strong><strong>)</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Clinical remission </strong><strong>at Week 48 </strong><strong>and endoscopic response<sup>d</sup></strong><strong> at Week 48</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>98 (34%)</p></td><td style="vertical-align:top"><p>119(42%)</p></td><td style="vertical-align:top"><p>140 (47%)</p></td></tr><tr><td style="vertical-align:top"><p>Biologic na&iuml;ve<sup>e</sup></p></td><td style="vertical-align:top"><p>52/121 (43%)</p></td><td style="vertical-align:top"><p>59/116 (51%)</p></td><td style="vertical-align:top"><p>70/128 (55%)</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic failure<sup>f</sup></p></td><td style="vertical-align:top"><p>40/156 (26%)</p></td><td style="vertical-align:top"><p>57/153 (37%)</p></td><td style="vertical-align:top"><p>60/147 (41%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Endoscopic response<sup>g</sup></strong><strong> at Week 48</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>108 (37%)</p></td><td style="vertical-align:top"><p>137 (48%)</p></td><td style="vertical-align:top"><p>156 (53%)</p></td></tr><tr><td style="vertical-align:top"><p>Biologic na&iuml;ve<sup>e</sup></p></td><td style="vertical-align:top"><p>52/121 (43%)</p></td><td style="vertical-align:top"><p>68/116 (59%)</p></td><td style="vertical-align:top"><p>76/128 (59%)</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic failure<sup>f</sup></p></td><td style="vertical-align:top"><p>49/156 (31%)</p></td><td style="vertical-align:top"><p>66/153 (43%)</p></td><td style="vertical-align:top"><p>69/147 (47%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Endoscopic remission<sup>h</sup></strong><strong> at Week 48</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>48 (16%)</p></td><td style="vertical-align:top"><p>72 (25%)</p></td><td style="vertical-align:top"><p>63 (21%)</p></td></tr><tr><td style="vertical-align:top"><p>Biologic na&iuml;ve<sup>e</sup></p></td><td style="vertical-align:top"><p>23/121 (19%)</p></td><td style="vertical-align:top"><p>39/116 (34%)</p></td><td style="vertical-align:top"><p>34/128 (27%)</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic failure<sup>f</sup></p></td><td style="vertical-align:top"><p>21/156 (13%)</p></td><td style="vertical-align:top"><p>32/153 (21%)</p></td><td style="vertical-align:top"><p>21/147 (14%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Clinical remission<sup>i</sup> at Week 48</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>183 (63%)</p></td><td style="vertical-align:top"><p>187 (65%)</p></td><td style="vertical-align:top"><p>208 (70%)</p></td></tr><tr><td style="vertical-align:top"><p>Biologic na&iuml;ve<sup>e</sup></p></td><td style="vertical-align:top"><p>91/121 (75%)</p></td><td style="vertical-align:top"><p>85/116 (73%)</p></td><td style="vertical-align:top"><p>98/128 (77%)</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic failure<sup>f</sup></p></td><td style="vertical-align:top"><p>82/156</p><p>(53%)</p></td><td style="vertical-align:top"><p>93/153 (61%)</p></td><td style="vertical-align:top"><p>94/147 (64%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Corticosteriod-free clinical remission<sup>j </sup></strong><strong>at Week 48</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>174 (60%)</p></td><td style="vertical-align:top"><p>182 (64%)</p></td><td style="vertical-align:top"><p>200 (68%)</p></td></tr><tr><td style="vertical-align:top"><p>Biologic na&iuml;ve<sup>e</sup></p></td><td style="vertical-align:top"><p>89/121 (74%)</p></td><td style="vertical-align:top"><p>82/116 (71%)</p></td><td style="vertical-align:top"><p>94/128 (73%)</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic failuref</p></td><td style="vertical-align:top"><p>75/156 (48%)</p></td><td style="vertical-align:top"><p>91/153 (59%)</p></td><td style="vertical-align:top"><p>92/147 (63%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>PRO-2 remission<sup>k </sup></strong><strong>at Week 48</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>163 (56%)</p></td><td style="vertical-align:top"><p>169 (59%)</p></td><td style="vertical-align:top"><p>185 (63%)</p></td></tr><tr><td style="vertical-align:top"><p>Biologic na&iuml;ve<sup>e</sup></p></td><td style="vertical-align:top"><p>81/121 (67%)</p></td><td style="vertical-align:top"><p>76/116 (66%)</p></td><td style="vertical-align:top"><p>86/128 (67%)</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic failure<sup>f</sup></p></td><td style="vertical-align:top"><p>73/156 (47%)</p></td><td style="vertical-align:top"><p>83/153 (54%)</p></td><td style="vertical-align:top"><p>84/147 (57%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; Ustekinumab 6&nbsp;mg/kg intravenous induction at Week 0 followed by ustekinumab 90&nbsp;mg subcutaneous q8w thereafter for up to 48 weeks.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp; Guselkumab 200&nbsp;mg intravenous induction at Week 0, Week 4 and Week 8 followed by guselkumab 100&nbsp;mg subcutaneous q8w thereafter for up to 48 weeks.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp; Guselkumab 200&nbsp;mg intravenous induction at Week 0, Week 4 and Week 8 followed by guselkumab 200&nbsp;mg subcutaneous q4w thereafter for up to 48 weeks.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp; A combination of clinical remission and endoscopic response as defined below.&nbsp;</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp; An additional 14 patients in the ustekinumab group, 21 patients in the guselkumab 200&nbsp;mg subcutaneous q4w group, and 17 patients in the guselkumab 100&nbsp;mg subcutaneous q8w group were previously exposed to but did not fail a biological therapy.</p><p><sup>f</sup>&nbsp;&nbsp;&nbsp;&nbsp; Includes inadequate response, loss of response, or intolerance to biologic therapy (TNF blockers, vedolizumab) for Crohn&rsquo;s disease.</p><p><sup>g</sup>&nbsp;&nbsp;&nbsp; Endoscopic response is defined as &ge; 50% improvement from baseline in SES-CD score or SES-CD Score &le; 2.</p><p><sup>h</sup>&nbsp;&nbsp;&nbsp; Endoscopic remission is defined as SES-CD Score &le; 2.</p><p><sup>i</sup>&nbsp;&nbsp;&nbsp;&nbsp; Clinical remission is defined as CDAI score &lt;150.</p><p><sup>j</sup>&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroid-free clinical remission is defined as CDAI score &lt;150 at Week 48 and not receiving corticosteroids at Week&nbsp;48.</p><p><sup>k</sup>&nbsp;&nbsp;&nbsp; PRO-2 remission is defined as AP mean daily score at or below 1 and SF mean daily score at or below 3, and no worsening of AP or SF from baseline.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>In GALAXI 2 and GALAXI 3, the efficacy and safety of guselkumab was consistently demonstrated regardless of age, sex, race and body weight. Guselkumab was efficacious in biologic naive patients, as well as in patients who previously failed a biologic.</p><p>&nbsp;</p><p>In the pooled GALAXI Phase 3 studies subpopulation analysis, patients with high inflammatory burden after completion of induction dosing derived additional benefit from guselkumab 200&nbsp;mg subcutaneous q4w compared to the 100&nbsp;mg subcutaneous q8w. A clinically meaningful difference of 10 to 17 percentage points was observed between the two guselkumab dose groups among patients with a CRP level of &gt;5 mg/L after completion of induction, for the endpoints of clinical remission at Week 48 (100&nbsp; mg subcutaneous q8w:&nbsp;54.1% vs 200&nbsp; mg subcutaneous q4w: 71.0%); endoscopic response at Week 48&nbsp;(100&nbsp;mg subcutaneous&nbsp;q8w:&nbsp;36.5% vs 200&nbsp;mg subcutaneous q4w:&nbsp;50.5%); and PRO-2&nbsp;remission at week&nbsp;48 (100&nbsp;mg subcutaneous q8w: 51.8% vs 200&nbsp;mg subcutaneous q4w: 61.7%).</p><p>&nbsp;</p><p><em>Week 48 outcomes after Week 12 clinical non-response</em></p><p>Guselkumab treated patients who were not in clinical response at Week&nbsp;12 after induction, received the maintenance dose regimen to which they were assigned at Week 0: guselkumab 100&nbsp;mg subcutaneous q8w or guselkumab 200&nbsp;mg subcutaneous q4w. In pooled GALAXI 2 and GALAXI 3, among patients without clinical response at Week 12, the proportion of patients achieving clinical remission at Week&nbsp;48 was 55.6% for the guselkumab 100&nbsp;mg subcutaneous q8w treatment group and 58.3% for the guselkumab 200&nbsp;mg subcutaneous q4w treatment group.</p><p>&nbsp;</p><p><em>Stool Frequency and abdominal pain</em></p><p>Reductions in stool frequency and abdominal pain subscores were observed as early as Week 4 in a greater proportion of patients treated with guselkumab 200&nbsp;mg intravenous compared to placebo, and continued improvement was observed through Week&nbsp;48 with both maintenance dose regimens of guselkumab.</p><p>&nbsp;</p><p><em>Clinical remission over time</em></p><p>CDAI scores were recorded at each patient visit. Through Week 48, the proportion of patients in clinical remission with both guselkumab maintenance dose regimens was similar or greater than the proportion of patients in clinical remission observed with the ustekinumab treatment group (Figure 8).</p><p>&nbsp;</p><p><strong>Figure 1:&nbsp;&nbsp;&nbsp;&nbsp; Proportion of patients in clinical remission through Week 48 in pooled GALAXI 2 and GALAXI 3</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_93" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:453.5pt;height:323pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="605" height="431" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Health-related quality of life</u></em></p><p>At Week 12 of GALAXI 2 and GALAXI 3 in the combined guselkumab 200&nbsp;mg intravenous induction group, patients showed significantly greater and clinically meaningful improvements in fatigue response compared to placebo as assessed by PROMIS Fatigue SF 7a (P&lt;0.05 and p&lt;0.001, respectively).</p><p>&nbsp;</p><p>Greater improvements from baseline were seen at Week 12 in guselkumab treatment groups when compared with placebo for inflammatory bowel disease (IBD)-specific quality of life assessed by IBDQ total score. All IBDQ domain scores (bowel symptoms, systemic symptoms, emotional function, and social function) and 6 of 7 general health-related quality of life domains of PROMIS-29 (i.e., depression, anxiety, physical function, pain interference, fatigue, and ability to participate in social roles and activities), as well as summary scores of overall physical health and mental health in both GALAXI 2 and GALAXI 3. Patients receiving guselkumab experienced greater improvements in overall work productivity and daily activity as assessed by the WPAI-CD questionnaire in GALAXI 2 and GALAXI 3 compared with the placebo treatment group at Week 12.</p><p>&nbsp;</p><p>All improvements in the above measures of health-related quality of life were maintained through Week 48 in both studies.</p><p>&nbsp;</p><p><em><u>Crohn&rsquo;s disease related hospitalisations and/or surgeries </u></em></p><p>Through Week 12 of GALAXI 2 and GALAXI 3, the proportions of patients with Crohn&rsquo;s disease related hospitalisations and/or surgeries were low: 2.1% in the combined guselkumab 200&nbsp;mg intravenous group and 5.4% in the placebo group.</p><p>Through Week 48 of GALAXI 2 and GALAXI 3, the proportions of patients with Crohn&rsquo;s disease related hospitalisations and/or surgeries were also low: 5.9% in the guselkumab 100&nbsp;mg subcutaneous q8w treatment group , and 5.1% in the guselkumab 200&nbsp;mg subcutaneous q4w treatment group.</p><p><em>GRAVITI</em></p><p>In the Phase III GRAVITI study, moderately to severely active Crohn&rsquo;s disease was defined as a CDAI score of &ge; 220 and &le; 450 and a CD (SES-CD) of &ge;6 (or &ge;4 for patients with isolated ileal disease) and a mean daily SF &ge; 4 or mean daily AP score &ge; 2.</p><p>&nbsp;</p><p>In GRAVITI, patients were randomised in a 1:1:1 ratio to receive guselkumab 400 mg subcutaneous induction at Weeks 0, 4 and 8 followed by guselkumab 100&nbsp;mg q8w subcutaneous maintenance; or guselkumab 400&nbsp;mg subcutaneous induction at Weeks 0, 4 and 8, followed by guselkumab 200&nbsp;mg q4w subcutaneous maintenance; or placebo. All patients in the placebo group who met rescue criteria received the induction dosing with guselkumab 400&nbsp;mg subcutaneous.</p><p>&nbsp;</p><p>A total of 347 patients were evaluated. The median age of patients was 36 years (ranging from 18 to 83 years), 58.5% were male, and 66% identified as White, 21.9% as Asian and 2.6% as Black.</p><p>&nbsp;</p><p>In GRAVITI, 46.4% of patients had previously failed treatment with at least one biologic therapy, 46.4 % were biologic na&iuml;ve, and 7.2% had previously received but had not failed a biologic. At baseline, 29.7% of the patients were receiving oral corticosteroids and 28.2% of the patients were receiving conventional immunomodulators.</p><p>&nbsp;</p><p>In GRAVITI, a significantly greater proportion of patients achieved co-primary efficacy endpoints of clinical remission at Week 12 and endoscopic response at Week 12 in the guselkumab treated group compared to placebo. A significantly greater proportion of patients in the guselkumab treated group achieved PRO-2 remission at Week 12, and clinical response at Week 12, compared with the placebo treatment group (Table 8).</p><p>&nbsp;</p><p>Clinical remission at Week 24 was achieved by a significantly greater proportion of patients treated with guselkumab 400 mg subcutaneous induction followed by guselkumab100&nbsp;mg subcutaneous q8w or 200&nbsp;mg subcutaneous q4w compared to placebo (60% and 58.3% vs 21.4% respectively, both p-values &lt;0.001).</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:89%"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Table&nbsp;8:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proportion of patients meeting short-term efficacy endpoints with guselkumab versus placebo at Week 12 in GRAVITI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=117)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Guselkumab 400</strong><strong>&nbsp;</strong><strong>mg</strong></p><p><strong>subcutaneous injection</strong><strong><sup>a</sup></strong></p><p><strong>&nbsp;(N=</strong><strong>230</strong><strong>)</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Clinical remission<sup>b</sup> at Week 12</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>25 (21%)</p></td><td colspan="3" style="vertical-align:top"><p>129 (56%)<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic na&iuml;ve<sup>d</sup></p></td><td style="vertical-align:top"><p>14/56 (25%)</p></td><td colspan="3" style="vertical-align:top"><p>52/105 (50%)</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic failure<sup>e</sup></p></td><td style="vertical-align:top"><p>9/53 (17%)</p></td><td colspan="3" style="vertical-align:top"><p>65/108 (60%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Endoscopic response<sup>f</sup> at Week 12</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>25 (21%)</p></td><td colspan="3" style="vertical-align:top"><p>95 (41%)<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic na&iuml;ve<sup>d</sup></p></td><td style="vertical-align:top"><p>15/56 (27%)</p></td><td colspan="3" style="vertical-align:top"><p>51/105 (49%)</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic failure<sup>e</sup></p></td><td style="vertical-align:top"><p>9/53 (17%)</p></td><td colspan="3" style="vertical-align:top"><p>36/108 (33%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Clinical response<sup>g</sup> at Week 12</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>39 (33%)</p></td><td colspan="3" style="vertical-align:top"><p>169 (73%)<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic na&iuml;ve<sup>d</sup></p></td><td style="vertical-align:top"><p>21/56 (38%)</p></td><td colspan="3" style="vertical-align:top"><p>71/105 (68%)</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic failure<sup>e</sup></p></td><td style="vertical-align:top"><p>15/53 (28%)</p></td><td colspan="3" style="vertical-align:top"><p>84/108 (78%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>PRO-2 remission<sup>h</sup> at Week 12</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>20 (17%)</p></td><td colspan="3" style="vertical-align:top"><p>113 (49%)<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic na&iuml;ve<sup>d</sup></p></td><td style="vertical-align:top"><p>10/56 (18%)</p></td><td colspan="3" style="vertical-align:top"><p>46/105 (44%)</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic failure<sup>e</sup></p></td><td style="vertical-align:top"><p>9/53 (17%)</p></td><td colspan="3" style="vertical-align:top"><p>56/108 (52%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp; Guselkumab 400&nbsp;mg subcutaneous at Week 0, Week 4 and Week 8</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp; Clinical remission: CDAI score &lt;150</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp; p&lt;0.001</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp; An additional 8 patients in the placebo group and 17 patients in the guselkumab 400&nbsp;mg subcutaneous group, were previously exposed to but did not fail a biological therapy.</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp; Includes inadequate response, loss of response, or intolerance to biologic therapy (TNF blockers, vedolizumab) for Crohn&rsquo;s disease.</p><p><sup>f</sup>&nbsp;&nbsp;&nbsp;&nbsp; Endoscopic response: &ge;50% improvement from baseline in SES-CD score.</p><p><sup>g</sup>&nbsp;&nbsp;&nbsp; Clinical response: &ge;100-point reduction from baseline in CDAI score or CDAI score &lt;150.</p><p><sup>h&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>PRO-2 remission: AP mean daily score at or below 1 and SF mean daily score at or below 3, and no worsening of AP or SF from baseline.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><em><u>&nbsp;</u></em></p><p><em><u>Stool frequency and abdominal pain</u></em></p><p>Reductions in stool frequency and abdominal pain subscores were observed as early as Week 4 in a greater proportion of patients treated with guselkumab 400&nbsp;mg subcutaneous compared to placebo, and continued improvement was observed through Week 12.</p><p>&nbsp;</p><p><em><u>Health-related quality of life</u></em></p><p>In GRAVITI, clinically meaningful improvements were observed in IBD-specific quality of life as assessed with IBDQ total score and IBDQ domain scores, and 5 out of 7 domains of PROMIS-29 (fatigue, pain interference, physical function, ability to participate in social roles and activities and sleep disturbance), pain intensity score, and physical and mental health summary scores at Week 12. Clinically meaningful improvements in IBDQ scores as well as all 7 domains scores of PROMIS-29 were observed at Week 24.</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><em><u>Ulcerative colitis (UC)</u></em></p><p>The efficacy and safety of guselkumab were evaluated in two Phase&nbsp;III multicentre, randomised, double-blind, placebo-controlled studies (QUASAR induction study and QUASAR maintenance study) in adult patients with moderately to severely active ulcerative colitis who had an inadequate response, loss of response, or intolerance to corticosteroids, conventional immunomodulators (AZA, 6-MP), biologic therapy (TNF blockers, vedolizumab), and/or a Janus kinase (JAK) inhibitor. In addition, efficacy and safety of guselkumab were evaluated in a randomised, double-blind, placebo-controlled, Phase IIb induction dose-finding study (QUASAR induction dose-ranging study).</p><p>&nbsp;</p><p>Disease activity was assessed by the modified Mayo score (mMS), a 3-component Mayo score (0-9) which consists of the sum of the following subscores (0 to 3 for each subscore): stool frequency (SFS), rectal bleeding (RBS), and findings on centrally reviewed endoscopy (ES). Moderately to severely active ulcerative colitis was defined as a mMS between 5 and 9, a RBS <u>&gt;</u>1, and an ES of 2 (defined by marked erythema, absent vascular pattern, friability, and/or erosions) or an ES of 3 (defined by spontaneous bleeding and ulceration).</p><p>&nbsp;</p><p><em>Induction study: QUASAR IS</em></p><p>In the induction study QUASAR IS, patients were randomised in a 3:2 ratio to receive either guselkumab 200&nbsp;mg or placebo by intravenous infusion at Week 0, Week 4, and Week 8. A total of 701 patients were evaluated. At baseline the median mMS was 7, with 35.5% of patients having a baseline mMS of 5 to 6 and 64.5% having a mMS of 7 to 9, and 67.9% of patients with a baseline ES of 3. The median age was 39 years (ranging from 18 to 79 years); 43.1% were female; and 72.5% identified as White, 21.4% as Asian and 1% as Black.</p><p>&nbsp;</p><p>Enrolled patients were permitted to use stable doses of oral aminosalicylates, methotrexate, 6-MP, AZA and/or oral corticosteroids. At baseline, 72.5% of patients were receiving aminosalicylates, 20.8% of patients were receiving immunomodulators (MTX, 6-MP, or AZA), and 43.1% of patients were receiving corticosteroids. Concomitant biologic therapies or JAK inhibitors were not permitted.</p><p>&nbsp;</p><p>A total of 49.1% of patients had previously failed at least one biologic therapy, and/or JAK inhibitor. Of these patients, 87.5%, 54.1% and 18% had previously failed a TNF blocker, vedolizumab or a JAK inhibitor, respectively, and 47.4% had failed treatment with 2 or more of these therapies. A total of 48.4% of patients were biologic and JAK inhibitor na&iuml;ve, and 2.6% had previously received but had not failed a biologic or JAK inhibitor.</p><p>&nbsp;</p><p>The primary endpoint was clinical remission as defined by the mMS at Week 12. Secondary endpoints at Week 12 included symptomatic remission, endoscopic healing, clinical response, histologic endoscopic mucosal healing, fatigue response and IBDQ remission (Table 9).</p><p>&nbsp;</p><p>Significantly greater proportions of patients were in clinical remission at Week 12 in the guselkumab treated group compared to the placebo group.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 9: Proportion of patients meeting efficacy endpoints at Week 12 in QUASAR IS </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=280)</strong></p></td><td style="vertical-align:top"><p><strong>Guselkumab </strong></p><p><strong>200&nbsp;mg intravenous induction<sup>a</sup></strong></p><p><strong>(N=421)</strong></p></td><td style="vertical-align:top"><p><strong>Treatment Difference</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Clinical remission<sup>b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>22 (8%)</p></td><td style="vertical-align:top"><p>95 (23%)</p></td><td style="vertical-align:top"><p>15% (10%, 20%)<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic and JAK inhibitor&nbsp; na&iuml;ve<sup>d</sup></p></td><td style="vertical-align:top"><p>16/137 (12%)</p></td><td style="vertical-align:top"><p>64/202 (32%)</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic and/or JAK inhibitor failure<sup>e</sup></p></td><td style="vertical-align:top"><p>5/136 (4%)</p></td><td style="vertical-align:top"><p>26/208 (13%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Symptomatic remission<sup>f</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>58(21%)</p></td><td style="vertical-align:top"><p>210 (50%)</p></td><td style="vertical-align:top"><p>29% (23%, 36%)<sup> c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic and JAK inhibitor na&iuml;ve<sup>d</sup></p></td><td style="vertical-align:top"><p>36/137 (26%)</p></td><td style="vertical-align:top"><p>122/202 (60%)</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic and/or JAK inhibitor failure<sup>e</sup></p></td><td style="vertical-align:top"><p>19/136 (14%)</p></td><td style="vertical-align:top"><p>80/208 (38%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Endoscopic healing<sup>g</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>31 (11%)</p></td><td style="vertical-align:top"><p>113 (27%)</p></td><td style="vertical-align:top"><p>16% (10%, 21%)<sup> c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic and JAK inhibitor na&iuml;ve<sup>d</sup></p></td><td style="vertical-align:top"><p>23/137 (17%)</p></td><td style="vertical-align:top"><p>77/202 (38%)</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic and/or JAK inhibitor failure<sup>e</sup></p></td><td style="vertical-align:top"><p>7/136 (5%)</p></td><td style="vertical-align:top"><p>31/208 (15%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical response<sup>h</sup></strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>78 (28%)</p></td><td style="vertical-align:top"><p>259 (62%)</p></td><td style="vertical-align:top"><p>34% (27%, 41%)<sup> c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic and JAK inhibitor na&iuml;ve<sup>d</sup></p></td><td style="vertical-align:top"><p>48/137 (35%)</p></td><td style="vertical-align:top"><p>144/202 (71%)</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic and/or JAK inhibitor failure<sup>e</sup></p></td><td style="vertical-align:top"><p>27/136 (20%)</p></td><td style="vertical-align:top"><p>107/208 (51%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Histologic endoscopic mucosal healing<sup>i</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>21 (8%)</p></td><td style="vertical-align:top"><p>99 (24%)</p></td><td style="vertical-align:top"><p>16% (11%, 21%)<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic and JAK inhibitor na&iuml;ve<sup>d</sup></p></td><td style="vertical-align:top"><p>15/137 (11%)</p></td><td style="vertical-align:top"><p>66/202 (33%)</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic and/or JAK inhibitor failure<sup>e</sup></p></td><td style="vertical-align:top"><p>6/136 (4%)</p></td><td style="vertical-align:top"><p>28/208 (13%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fatigue response</strong><sup>j</sup></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>60 (21%)</p></td><td style="vertical-align:top"><p>173 (41%)</p></td><td style="vertical-align:top"><p>20% (13%, 26%)<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic and JAK inhibitor na&iuml;ve<sup>d</sup></p></td><td style="vertical-align:top"><p>40/137 (29%)</p></td><td style="vertical-align:top"><p>84/202 (42%)</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic and/or JAK inhibitor failure<sup>e</sup></p></td><td style="vertical-align:top"><p>18/136 (13%)</p></td><td style="vertical-align:top"><p>80/208 (38%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>IBDQ remission<sup>k</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>83 (30%)</p></td><td style="vertical-align:top"><p>216 (51%)</p></td><td style="vertical-align:top"><p>22% (15%, 29%)<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic and JAK inhibitor na&iuml;ve<sup>d</sup></p></td><td style="vertical-align:top"><p>47/137 (34%)</p></td><td style="vertical-align:top"><p>126/202 (62%)</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic and/or JAK inhibitor failure<sup>e</sup></p></td><td style="vertical-align:top"><p>33/136 (24%)</p></td><td style="vertical-align:top"><p>82/208 (39%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Guselkumab 200&nbsp;mg as an intravenous induction at Week 0, Week 4, and Week 8.<sup> </sup></p><p><sup>b</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>A stool frequency subscore of 0 or 1 and not increased from baseline, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy.</p><p><sup>c</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>p &lt;0.001, adjusted treatment difference (95% CI) based on Cochran-Mantel-Haenszel method (adjusted for stratification factors: biologic and/or JAK-inhibitor failure status and concomitant use of corticosteroids at baseline).</p><p><sup>d</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>An additional 7 patients in the placebo group and 11 patients in the guselkumab group were previously exposed to but did not fail a biologic or JAK inhibitor.</p><p><sup>e</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Includes inadequate response, loss of response, or intolerance to biologic therapy (TNF blockers, vedolizumab) and/or a Janus kinase (JAK) inhibitor for ulcerative colitis.</p><p><sup>f</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>A stool frequency subscore of 0 or 1 and not increased from induction baseline, and a rectal bleeding subscore of 0.</p><p><sup>g</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>An endoscopy subscore of 0 or 1 with no friability present on the endoscopy.</p><p><sup>h</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Decrease from induction baseline in the modified Mayo score by &ge;30% and &ge;2 points, with either a &ge;1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1.</p><p><sup>i</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>A combination of histologic healing [neutrophil infiltration in &lt;5% of crypts, no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system] and endoscopic healing as defined above.</p><p><sup>j</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Fatigue was assessed using the PROMIS-Fatigue Short form 7a. Fatigue response was defined as a &ge; 7-point improvement from baseline which is considered clinically meaningful.</p><p><sup>k&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Total Inflammatory Bowel Disease Questionnaire score &ge;170.</p></td></tr></tbody></table><p>&nbsp;</p><p>QUASAR IS and QUASAR induction dose-ranging study also enrolled patients with a baseline mMS of 4, including an ES of 2 or 3 and a RBS &ge;1. In these patients, guselkumab efficacy relative to placebo, as measured by clinical remission, clinical response, and endoscopic healing at Week 12, was consistent with the total moderately to severely active UC population.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Rectal bleeding and stool frequency subscores</u></em></p><p>Decreases in rectal bleeding and stool frequency subscores were observed as early as Week 2 in patients treated with guselkumab and continued to decrease through Week 12.</p><p>&nbsp;</p><p><em>Maintenance study: QUASAR MS</em></p><p>The QUASAR MS evaluated 568 patients who achieved clinical response at 12 weeks following the intravenous administration of guselkumab in either QUASAR IS or from the QUASAR induction dose-ranging study. In the QUASAR MS, these patients were randomised to receive a subcutaneous maintenance regimen of either guselkumab 100&nbsp;mg every 8 weeks, guselkumab 200&nbsp;mg every 4 weeks or placebo for 44 weeks.</p><p>&nbsp;</p><p>The primary endpoint was clinical remission as defined by mMS at Week 44. Secondary endpoints at Week 44 included but were not limited to symptomatic remission, endoscopic healing, corticosteroid-free clinical remission, histologic endoscopic mucosal healing, fatigue response and IBDQ remission (Table 10).</p><p>&nbsp;</p><p>Significantly greater proportions of patients were in clinical remission at Week 44 in both guselkumab treated groups compared to the placebo.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="6" style="vertical-align:top"><p><strong>Table 10:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proportion of patients meeting efficacy endpoints at Week 44 in QUASAR MS</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=190)</strong></p><p><strong>&nbsp;</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Guselkumab 100&nbsp;mg q8w</strong></p><p><strong>subcutaneous injection<sup>a</sup></strong></p><p><strong>(N=188)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Guselkumab 200&nbsp;mg q4w</strong></p><p><strong>subcutaneous injection<sup>b</sup></strong></p><p><strong>(N=190)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Treatment Difference </strong></p><p><strong>vs Placebo</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Guselkumab 100 mg</strong></p></td><td style="vertical-align:top"><p><strong>Guselkumab 200 mg</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Clinical remission<sup>c</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population<sup>d</sup></p></td><td style="vertical-align:top"><p>36 (19%)</p></td><td style="vertical-align:top"><p>85 (45%)</p></td><td style="vertical-align:top"><p>95 (50%)</p></td><td style="vertical-align:top"><p>25%</p><p>(16%, 34%)<sup>e </sup></p></td><td style="vertical-align:top"><p>30%</p><p>(21%, 38%)<sup>e</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic and JAK-inhibitor na&iuml;ve<sup>f</sup></p></td><td style="vertical-align:top"><p>28/108 (26%)</p></td><td style="vertical-align:top"><p>53/105 (50%)</p></td><td style="vertical-align:top"><p>56/96 (58%)</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic and/or JAK-inhibitor failure<sup>g</sup></p></td><td style="vertical-align:top"><p>6/75 (8%)</p></td><td style="vertical-align:top"><p>31/77 (40%)</p></td><td style="vertical-align:top"><p>35/88 (40%)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Symptomatic remission<sup>h</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population<sup>d</sup></p></td><td style="vertical-align:top"><p>71 (37%)</p></td><td style="vertical-align:top"><p>132 (70%)</p></td><td style="vertical-align:top"><p>131 (69%)</p></td><td style="vertical-align:top"><p>32%</p><p>(23%, 41%)<sup>e</sup></p></td><td style="vertical-align:top"><p>31%</p><p>(21%, 40%)<sup>e</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic and JAK-inhibitor na&iuml;ve<sup>f</sup></p></td><td style="vertical-align:top"><p>50/108 (46%)</p></td><td style="vertical-align:top"><p>78/105 (74%)</p></td><td style="vertical-align:top"><p>73/96 (76%)</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic and/or JAK-inhibitor failure<sup> g</sup></p></td><td style="vertical-align:top"><p>18/75 (24%)</p></td><td style="vertical-align:top"><p>50/77 (65%)</p></td><td style="vertical-align:top"><p>53/88 (60%)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Corticosteroid-free clinical remission<sup>i </sup></strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Total population<sup>d</sup></p></td><td style="vertical-align:top"><p>35 (18%)</p></td><td style="vertical-align:top"><p>85 (45%)</p></td><td style="vertical-align:top"><p>93 (49%)</p></td><td style="vertical-align:top"><p>26%</p><p>(17%, 34%)<sup>e</sup></p></td><td style="vertical-align:top"><p>29%</p><p>(20%, 38%)<sup>e</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic and JAK-inhibitor na&iuml;ve<sup>f</sup></p></td><td style="vertical-align:top"><p>28/108 (26%)</p></td><td style="vertical-align:top"><p>53/105 (50%)</p></td><td style="vertical-align:top"><p>54/96 (56%)</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic and/or JAK-inhibitor failure<sup> g</sup></p></td><td style="vertical-align:top"><p>5/75 (7%)</p></td><td style="vertical-align:top"><p>31/77 (40%)</p></td><td style="vertical-align:top"><p>35/88 (40%)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Endoscopic healing<sup>j</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population<sup>d</sup></p></td><td style="vertical-align:top"><p>36 (19%)</p></td><td style="vertical-align:top"><p>93 (49%)</p></td><td style="vertical-align:top"><p>98 (52%)</p></td><td style="vertical-align:top"><p>30%</p><p>(21%, 38%)<sup>e</sup></p></td><td style="vertical-align:top"><p>31%</p><p>(22%, 40%)<sup>e</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic and JAK-inhibitor na&iuml;ve<sup>f</sup></p></td><td style="vertical-align:top"><p>28/108 (26%)</p></td><td style="vertical-align:top"><p>56/105 (53%)</p></td><td style="vertical-align:top"><p>57/96 (59%)</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic and/or JAK-inhibitor failure<sup> g</sup></p></td><td style="vertical-align:top"><p>6/75 (8%)</p></td><td style="vertical-align:top"><p>35/77 (45%)</p></td><td style="vertical-align:top"><p>37/88 (42%)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Histologic endoscopic mucosal healing<sup>k</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population<sup>d</sup></p></td><td style="vertical-align:top"><p>32 (17%)</p></td><td style="vertical-align:top"><p>82 (44%)</p></td><td style="vertical-align:top"><p>91 (48%)</p></td><td style="vertical-align:top"><p>26%</p><p>(17%, 34%)<sup>e</sup></p></td><td style="vertical-align:top"><p>30%</p><p>(21%, 38%)<sup>e</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic and JAK-inhibitor na&iuml;ve<sup>f</sup></p></td><td style="vertical-align:top"><p>25/108 (23%)</p></td><td style="vertical-align:top"><p>52/105 (50%)</p></td><td style="vertical-align:top"><p>54/96 (56%)</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic and/or JAK-inhibitor failure<sup>g</sup></p></td><td style="vertical-align:top"><p>6/75 (8%)</p></td><td style="vertical-align:top"><p>29/77 (38%)</p></td><td style="vertical-align:top"><p>34/88 (39%)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Clinical response<sup>l</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population<sup>d</sup></p></td><td style="vertical-align:top"><p>82 (43%)</p></td><td style="vertical-align:top"><p>146 (78%)</p></td><td style="vertical-align:top"><p>142 (75%)</p></td><td style="vertical-align:top"><p>34%</p><p>(25%, 43%)<sup>e</sup></p></td><td style="vertical-align:top"><p>31%</p><p>(21%, 40%)<sup>e</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic and JAK-inhibitor na&iuml;ve<sup>f</sup></p></td><td style="vertical-align:top"><p>58/108 (54%)</p></td><td style="vertical-align:top"><p>87/105 (83%)</p></td><td style="vertical-align:top"><p>78/96 (81%)</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic and/or JAK-inhibitor failure<sup> g</sup></p></td><td style="vertical-align:top"><p>21/75 (28%)</p></td><td style="vertical-align:top"><p>54/77 (70%)</p></td><td style="vertical-align:top"><p>59/88 (67%)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Maintenance of Clinical Remission at Week 44 in patients who achieved clinical remission 12 weeks after induction</strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population<sup>d</sup></p></td><td style="vertical-align:top"><p>20/59 (34%)</p></td><td style="vertical-align:top"><p>40/66 (61%)</p></td><td style="vertical-align:top"><p>50/69 (72%)</p></td><td style="vertical-align:top"><p>26%</p><p>(9%, 43%)<sup>m</sup></p></td><td style="vertical-align:top"><p>38%</p><p>(23%, 54%)<sup>e</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic and JAK-inhibitor na&iuml;ve <sup>f</sup></p></td><td style="vertical-align:top"><p>14/41 (34%)</p></td><td style="vertical-align:top"><p>28/43 (65%)</p></td><td style="vertical-align:top"><p>38/48 (79%)</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic and/or JAK-inhibitor failure<sup> g</sup></p></td><td style="vertical-align:top"><p>4/15 (27%)</p></td><td style="vertical-align:top"><p>12/20 (60%)</p></td><td style="vertical-align:top"><p>10/18 (56%)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Endoscopic normalisation<sup>n</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population<sup>d</sup></p></td><td style="vertical-align:top"><p>29 (15%)</p></td><td style="vertical-align:top"><p>65 (35%)</p></td><td style="vertical-align:top"><p>64 (34%)</p></td><td style="vertical-align:top"><p>18%</p><p>(10%, 27%)<sup>e</sup></p></td><td style="vertical-align:top"><p>17%</p><p>(9%, 25%)<sup>e</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic and JAK-inhibitor na&iuml;ve <sup>f</sup></p></td><td style="vertical-align:top"><p>22/108 (20%)</p></td><td style="vertical-align:top"><p>40/105 (38%)</p></td><td style="vertical-align:top"><p>40/96 (42%)</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic and/or JAK-inhibitor failure<sup> g</sup></p></td><td style="vertical-align:top"><p>6/75 (8%)</p></td><td style="vertical-align:top"><p>24/77 (31%)</p></td><td style="vertical-align:top"><p>21/88 (24%)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Fatigue response<sup>o</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population <sup>d</sup></p></td><td style="vertical-align:top"><p>56 (29%)</p></td><td style="vertical-align:top"><p>95 (51%)</p></td><td style="vertical-align:top"><p>82 (43%)</p></td><td style="vertical-align:top"><p>20%</p><p>(11%, 29%)<sup>e</sup></p></td><td style="vertical-align:top"><p>13%</p><p>(3%, 22%)<sup>m</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic and JAK-inhibitor na&iuml;ve<sup>f</sup></p></td><td style="vertical-align:top"><p>39/108 (36%)</p></td><td style="vertical-align:top"><p>54/105 (51%)</p></td><td style="vertical-align:top"><p>51/96 (53%)</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic and/or JAK-inhibitor failure<sup> g</sup></p></td><td style="vertical-align:top"><p>14/75 (19%)</p></td><td style="vertical-align:top"><p>36/77 (47%)</p></td><td style="vertical-align:top"><p>28/88 (32%)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>IBDQ remission<sup>p</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Total population<sup>d</sup></p></td><td style="vertical-align:top"><p>71 (37%)</p></td><td style="vertical-align:top"><p>121 (64%)</p></td><td style="vertical-align:top"><p>122 (64%)</p></td><td style="vertical-align:top"><p>26%</p><p>(17%, 36%)<sup>e</sup></p></td><td style="vertical-align:top"><p>26%</p><p>(16%, 35%)<sup>e</sup></p></td></tr><tr><td style="vertical-align:top"><p>Biologic and JAK-inhibitor na&iuml;ve <sup>f</sup></p></td><td style="vertical-align:top"><p>53/108 (49%)</p></td><td style="vertical-align:top"><p>71/105 (68%)</p></td><td style="vertical-align:top"><p>71/96 (74%)</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior biologic and/or JAK-inhibitor failure<sup> g</sup></p></td><td style="vertical-align:top"><p>14/75 (19%)</p></td><td style="vertical-align:top"><p>45/77 (58%)</p></td><td style="vertical-align:top"><p>47/88 (53%)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>a</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Guselkumab 100&nbsp;mg as a subcutaneous injection every 8 weeks after the induction regimen.</p><p><sup>b</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Guselkumab 200&nbsp;mg as a subcutaneous injection every 4 weeks after the induction regimen.</p><p><sup>c</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>A stool frequency subscore of 0 or 1 and not increased from baseline, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy.</p><p><sup>d</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Patients who achieved clinical response 12 weeks following the intravenous administration of guselkumab in either QUASAR induction study or QUASAR induction dose-ranging study.</p><p><sup>e</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>p &lt;0.001, adjusted treatment difference (95% CI) based on Cochran-Mantel-Haenszel method adjusted for randomisation stratification factors.</p><p><sup>f</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>An additional 7 patients in the placebo group, 6 patients in the guselkumab 100&nbsp;mg group, and 6 patients in the guselkumab 200&nbsp;mg group were previously exposed to but did not fail a biologic or JAK inhibitor.</p><p><sup>g</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Includes inadequate response, loss of response, or intolerance to biologic therapy (TNF blockers, vedolizumab) and/or a Janus kinase [JAK] inhibitor for ulcerative colitis.</p><p><sup>h</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>A stool frequency subscore of 0 or 1 and not increased from induction baseline, and a rectal bleeding subscore of 0.</p><p><sup>i</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Not requiring any treatment with corticosteroids for at least 8 weeks prior to Week 44 and also meeting the criteria for clinical remission at Week 44.</p><p><sup>j</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>An endoscopy subscore of 0 or 1 with no friability present on the endoscopy.</p><p><sup>k</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>A combination of histologic healing [neutrophil infiltration in &lt;5% of crypts, no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system] and endoscopic healing as defined above.</p><p><sup>l</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Decrease from induction baseline in the modified Mayo score by &ge;30% and &ge;2 points, with either a &ge;1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1.</p><p><sup>m&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>p &lt;0.01, adjusted treatment difference (95% CI) based on Cochran-Mantel-Haenszel method adjusted for randomization stratification factors</p><p><sup>n</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>An endoscopy subscore of 0.</p><p><sup>o</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Fatigue was assessed using the PROMIS-Fatigue Short form 7a. Fatigue response was defined as a &ge; 7-point improvement from induction baseline which is considered clinically meaningful.</p><p><sup>p</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Total Inflammatory Bowel Disease Questionnaire score &ge;170.</p></td></tr></tbody></table><p>&nbsp;</p><p>In QUASAR IS and QUASAR MS, the efficacy and safety of guselkumab was consistently demonstrated regardless of age, sex, race, body weight, and previous treatment with a biologic therapy or JAK inhibitor. Guselkumab was efficacious in biologic and JAK inhibitor na&iuml;ve patients, as well as in patients who previously failed a biologic and/or JAK inhibitor.</p><p>&nbsp;</p><p>In QUASAR MS, patients with high inflammatory burden after completion of induction dosing derived additional benefit from guselkumab 200&nbsp;mg subcutaneous q4w compared to 100&nbsp;mg subcutaneous q8w dosing. Clinically meaningful numerical differences of &gt;15% were observed between the two guselkumab dose groups among patients with a CRP level of &gt;3 mg/L after completion of induction dosing for the following endpoints at Week 44: clinical remission (48% 200&nbsp;mg q4w vs. 30% 100&nbsp;mg q8w), maintenance of clinical remission (88% 200&nbsp;mg q4w vs. 50% 100&nbsp;mg q8w), corticosteroid-free clinical remission (46% 200&nbsp;mg q4w vs. 30% 100&nbsp;mg q8w), endoscopic healing (52% 200&nbsp;mg q4w vs. 35% 100&nbsp;mg q8w), and histologic-endoscopic mucosal healing (46% 200&nbsp;mg q4w vs. 29% 100&nbsp;mg q8w).</p><p>&nbsp;</p><p>QUASAR MS also enrolled patients with an induction baseline mMS of 4, including an ES of 2 or 3 and a RBS &ge;1 who achieved clinical response 12 weeks following the intravenous administration of guselkumab in QUASAR IS or QUASAR induction dose-ranging study. In these patients, guselkumab efficacy relative to placebo as measured by clinical remission, clinical response, and endoscopic healing at Week 44 was consistent with the total population.</p><p>&nbsp;</p><p><em><u>Symptomatic remission over time</u></em></p><p>In QUASAR MS symptomatic remission defined as stool frequency subscore of 0 or 1 and not increased from induction baseline, and a rectal bleeding subscore of 0 was sustained through Week 44 in both guselkumab treatment groups, while a decline was observed in the placebo group (Figure 8):</p><p>&nbsp;</p><p>Figure&nbsp;2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proportion of patients in symptomatic remission through Week&nbsp;44 in QUASAR MS</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_1" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:378.5pt;
 height:282.5pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ERizk/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="505" height="377" src="data:image/jpeg;base64,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" /></p><p>&nbsp;</p><p><em><u>Week 24 responders to guselkumab </u></em></p><p>Guselkumab treated patients who were not in clinical response at induction Week 12, received guselkumab 200&nbsp;mg subcutaneous at induction Weeks 12, 16 and 20. In QUASAR IS, 66/120 (55%) guselkumab treated patients who were not in clinical response at induction Week 12 achieved clinical response at induction Week 24. Week 24 responders to guselkumab entered QUASAR MS and received guselkumab 200&nbsp;mg subcutaneous every 4 weeks. At Week 44 of QUASAR MS, 83/123 (68%) of these patients maintained clinical response and 37/123 (30%) achieved clinical remission.</p><p>&nbsp;</p><p><em><u>Recapture of efficacy after loss of response to guselkumab </u></em></p><p>Nineteen patients receiving guselkumab 100&nbsp;mg subcutaneous q8w who experienced a first loss of response (10%) between Week 8 and 32 of QUASAR MS received blinded guselkumab dosing with 200&nbsp;mg guselkumab subcutaneous q4w and 11 of these patients (58%) achieved symptomatic response and 5 patients (26%) achieved symptomatic remission after 12 weeks.</p><p>&nbsp;</p><p><em><u>Histologic and endoscopic assessment </u></em></p><p>Histologic remission was defined as a Geboes histologic score &le;2 B.0 (absence of neutrophils from the mucosa [both lamina propria and epithelium], no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system). In QUASAR IS, histologic remission at Week 12 was achieved in 40% of patients treated with guselkumab and 19% of patients in the placebo group. In QUASAR MS, histologic remission at Week 44 was achieved in 59% and 61% of patients treated with guselkumab 100&nbsp;mg subcutaneous q8w and guselkumab 200&nbsp;mg subcutaneous q4w and 27% of patients in the placebo group.</p><p>&nbsp;</p><p>Normalisation of the endoscopic appearance of the mucosa was defined as ES of 0. In QUASAR IS, endoscopic normalisation at Week 12 was achieved in 15% of patients treated with guselkumab and 5% of patients in the placebo group. In QUASAR MS, endoscopic normalisation at Week 44 was achieved in 35% and 34% of patients treated with guselkumab 100&nbsp;mg subcutaneous q8w and guselkumab 200&nbsp;mg subcutaneous q4w compared to 15% of patients on placebo.</p><p>&nbsp;</p><p><em><u>Composite histologic-endoscopic mucosal outcomes</u></em></p><p>Combined endoscopic normalisation and histologic remission at Week 44 was achieved by a greater proportion of patients treated with guselkumab 100&nbsp;mg subcutaneous q8w or 200&nbsp;mg subcutaneous q4w compared to placebo (31% and 33% vs 14%, respectively).</p><p>&nbsp;</p><p>Combined symptomatic remission, endoscopic healing, histologic healing, and fecal calprotectin &le;250&nbsp;mg/kg at Week 44 was achieved by a greater proportion of patients treated with guselkumab 100&nbsp;mg SC q8w or 200&nbsp;mg SC q4w compared to placebo (31% and 35% vs 11%, respectively).</p><p>&nbsp;</p><p>Combined symptomatic remission, endoscopic normalisation, histologic remission, and fecal calprotectin &le;250&nbsp;mg/kg at Week 44 was achieved by a greater proportion of patients treated with guselkumab 100&nbsp;mg subcutaneous q8w or 200&nbsp;mg subcutaneous q4w compared to placebo (22% and 28% vs 9%, respectively).</p><p>&nbsp;</p><p><em><u>Health-related quality of life</u></em></p><p>At Week 12 of QUASAR IS, patients receiving guselkumab showed greater and clinically meaningful improvements from baseline when compared with placebo in inflammatory bowel disease (IBD)-specific quality of life assessed by IBDQ total score, all IBDQ domain scores (bowel symptoms including abdominal pain and bowel urgency, systemic function, emotional function, and social function) and in fatigue by PROMIS Fatigue SF 7a. Clinically meaningful improvements in general health-related quality of life were seen in all 7 domains of PROMIS-29 (i.e., depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities), as well as in summary scores of overall physical health and mental health. These improvements in health-related quality of life measures (IBDQ, PROMIS-Fatigue SF 7a, PROMIS-29) were maintained in guselkumab-treated patients in QUASAR MS through Week 44.</p><p>&nbsp;</p><p>Patients receiving guselkumab experienced greater improvements in overall work productivity and daily activity as assessed by the WPAI-GH questionnaire when compared to patients receiving placebo. These improvements in work productivity were maintained in guselkumab treated patients in QUASAR MS through Week 44.</p><p>&nbsp;</p><p><em><u>Ulcerative colitis (UC) related hospitalisations and surgeries</u></em></p><p>Through Week 12 of QUASAR IS, lower proportions of patients in the guselkumab group compared with the placebo group had UC-related hospitalisations (1.9%, 8/421 vs. 5.4%, 15/280). The proportions of patients who underwent UC-related surgeries was 0.5% (2/421) in the guselkumab group and 0.7% (2/280) in the placebo group.</p><p>&nbsp;</p><p>Through Week 44 of QUASAR MS, the proportions of patients with UC-related hospitalisation were 1.6% (3/188) in the guselkumab 100&nbsp;mg subcutaneous q8w group, 1.1% (2/190) in the guselkumab 200&nbsp;mg subcutaneous q4w group and 0.5% (1/190) in the placebo group. There were no reported UC-related surgeries across the guselkumab and placebo groups.&nbsp;</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with guselkumab in one or more subsets of the paediatric population in Crohn&rsquo;s disease and ulcerative colitis (see section&nbsp;4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>Following a single 100&nbsp;mg subcutaneous injection in healthy subjects, guselkumab reached a mean (&plusmn;&nbsp;SD) maximum serum concentration (C<sub>max</sub>) of 8.09&nbsp;&plusmn;&nbsp;3.68&nbsp;mcg/mL by approximately 5.5&nbsp;days post dose. The absolute bioavailability of guselkumab following a single 100&nbsp;mg subcutaneous injection was estimated to be approximately 49% in healthy subjects.</p><p>&nbsp;</p><p>In patients with plaque psoriasis, following subcutaneous administrations of guselkumab 100&nbsp;mg at Weeks&nbsp;0 and&nbsp;4, and every 8&nbsp;weeks thereafter, steady‑state serum guselkumab concentrations were achieved by Week&nbsp;20. The mean (&plusmn;&nbsp;SD) steady‑state trough serum guselkumab concentrations in two Phase&nbsp;III studies in patients with plaque psoriasis were 1.15&nbsp;&plusmn;&nbsp;0.73&nbsp;mcg/mL and 1.23&nbsp;&plusmn;&nbsp;0.84&nbsp;mcg/mL.</p><p>The pharmacokinetics of guselkumab in patients with psoriatic arthritis was similar to that in patients with psoriasis. Following subcutaneous administration of guselkumab 100&nbsp;mg at Weeks&nbsp;0, 4, and every 8&nbsp;weeks thereafter, mean steady-state trough serum guselkumab concentration was also approximately 1.2&nbsp;mcg/mL. Following subcutaneous administration of guselkumab 100&nbsp;mg every 4&nbsp;weeks, mean steady-state trough serum guselkumab concentration was approximately 3.8&nbsp;mcg/mL.</p><p>&nbsp;</p><p>The pharmacokinetics of guselkumab were similar in patients with Crohn&rsquo;s disease and ulcerative colitis. Following the recommended intravenous induction dose regimen of guselkumab 200&nbsp;mg at Weeks 0, 4, and 8, mean peak serum guselkumab concentration at Week 8 was 70.5 mcg/mL in patients with Crohn&rsquo;s disease, and 68.27&nbsp;mcg/mL in patients with ulcerative colitis.</p><p>&nbsp;</p><p>Following the recommended subcutaneous induction dose regimen of guselkumab 400&nbsp;mg at Weeks 0, 4, and 8, mean peak serum concentration was estimated to be 27.7&nbsp;mcg/mL in patients with Crohn&rsquo;s disease. The total systemic exposure (AUC) after the recommended induction dose regimen was similar following subcutaneous and intravenous induction.</p><p>Following subcutaneous maintenance dosing of guselkumab 100&nbsp;mg every 8 weeks or guselkumab 200&nbsp;mg every 4 weeks in patients with Crohn&rsquo;s disease, mean steady-state trough serum guselkumab concentrations were approximately 1.2&nbsp;mcg/mL and 10.1&nbsp;mcg/mL, respectively.</p><p>&nbsp;</p><p>Following subcutaneous maintenance dosing of guselkumab 100&nbsp;mg every 8 weeks or guselkumab 200&nbsp;mg every 4 weeks in patients with ulcerative colitis, mean steady-state trough serum guselkumab concentrations were approximately 1.4&nbsp;mcg/mL and 10.7&nbsp;mcg/mL, respectively.</p><p>&nbsp;</p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>Mean volume of distribution during the terminal phase (V<sub>z</sub>) following a single intravenous administration to healthy subjects ranged from approximately 7&nbsp;to 10&nbsp;L across studies.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><u>&nbsp;</u></p><p>The exact pathway through which guselkumab is metabolised has not been characterised. As a human IgG mAb, guselkumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Mean systemic clearance (CL) following a single intravenous administration to healthy subjects ranged from 0.288&nbsp;to 0.479&nbsp;L/day across studies. Mean half‑life (T<sub>1/2</sub>) of guselkumab was approximately 17&nbsp;days in healthy subjects and approximately 15&nbsp;to 18&nbsp;days in patients with plaque psoriasis across studies, and approximately 17 days in patients with Crohn&rsquo;s disease and<strong> </strong>ulcerative colitis.</p><p>&nbsp;</p><p>Population pharmacokinetic analyses indicated that concomitant use of NSAIDs, AZA, zathioprine, 6-MP, oral corticosteroids and csDMARDs such as methotrexate, did not affect the clearance of guselkumab.</p><p>&nbsp;</p><p><u>Linearity/non‑linearity</u></p><p>&nbsp;</p><p>The systemic exposure of guselkumab (C<sub>max</sub> and AUC) increased in an approximately dose‑proportional manner following a single subcutaneous injection at doses ranging from 10&nbsp;mg to 300&nbsp;mg in healthy subjects or patients with plaque psoriasis. Serum guselkumab concentrations were approximately dose proportional following intravenous administration in patients with Crohn&rsquo;s disease or ulcerative colitis.</p><p>&nbsp;</p><p><u>Paediatric patients</u></p><p>&nbsp;</p><p>The pharmacokinetics of guselkumab in paediatric patients have not been established.</p><p><u>&nbsp;</u></p><p><u>Elderly patients</u></p><p>&nbsp;</p><p>No specific studies have been conducted in elderly patients. Of the 1384 plaque psoriasis patients exposed to guselkumab in Phase&nbsp;III clinical studies and included in the population pharmacokinetic analysis, 70&nbsp;patients were 65&nbsp;years of age or older, including 4&nbsp;patients who were 75&nbsp;years of age or older. Of the 746 psoriatic arthritis patients exposed to guselkumab in Phase&nbsp;III clinical studies, a total of 38&nbsp;patients were 65&nbsp;years of age or older, and no patients were 75&nbsp;years of age or older. Of the 1009 Crohn&rsquo;s disease patients exposed to guselkumab in Phase&nbsp;III clinical studies and included in the population pharmacokinetic analysis, a total of 39&nbsp;patients were 65&nbsp;years of age or older, and 5 patients were 75&nbsp;years of age or older.<strong> </strong>Of the 859 ulcerative colitis patients exposed to guselkumab in Phase&nbsp;II/III clinical studies and included in the population pharmacokinetic analysis, a total of 52&nbsp;patients were 65&nbsp;years of age or older, and 9 patients were 75&nbsp;years of age or older.</p><p>&nbsp;</p><p>Population pharmacokinetic analyses in plaque psoriasis, psoriatic arthritis, Crohn&rsquo;s disease and ulcerative colitis patients indicated no apparent changes in CL/F estimate in patients &ge;&nbsp;65&nbsp;years of age compared to patients &lt;&nbsp;65&nbsp;years of age, suggesting no dose adjustment is needed for elderly patients.</p><p>&nbsp;</p><p><u>Patients with renal or hepatic impairment</u></p><p>&nbsp;</p><p>No specific study has been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of guselkumab. Renal elimination of intact guselkumab, an IgG mAb, is expected to be low and of minor importance; similarly, hepatic impairment is not expected to influence clearance of guselkumab as IgG mAbs are mainly eliminated via intracellular catabolism. Based on population pharmacokinetic analyses, creatinine clearance or hepatic function did not have a meaningful impact on guselkumab clearance.</p><p>&nbsp;</p><p><u>Body weight</u></p><p><u>&nbsp;</u></p><p>Clearance and volume of distribution of guselkumab increases as body weight increases, however, observed clinical trial data indicate that dose adjustment for body weight is not warranted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‑clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeat‑dose toxicity, toxicity to reproduction and pre‑ and post‑natal development.</p><p>&nbsp;</p><p>In repeat‑dose toxicity studies in cynomolgus monkeys, guselkumab was well tolerated via intravenous and subcutaneous routes of administration. A weekly subcutaneous dose of 50&nbsp;mg/kg to monkeys resulted in exposure (AUC) values that were at least 23 times the maximum clinical exposures following a dose of 200&nbsp;mg given intravenously. Additionally, there were no adverse immunotoxicity or cardiovascular safety pharmacology effects noted during the conduct of the repeat‑dose toxicity studies or in a targeted cardiovascular safety pharmacology study in cynomolgus monkeys.</p><p>&nbsp;</p><p>There were no preneoplastic changes observed in histopathology evaluations of animals treated up to 24 weeks, or following the 12‑week recovery period during which active substance was detectable in the serum.</p><p>&nbsp;</p><p>No mutagenicity or carcinogenicity studies were conducted with guselkumab.</p><p>&nbsp;</p><p>Guselkumab could not be detected in breast milk from cynomolgus monkeys as measured at post‑natal day&nbsp;28.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pre</u><u>‑filled syringe</u><u> </u></p><p>Histidine</p><p>Histidine monohydrochloride monohydrate</p><p>Polysorbate 80 (E433)</p><p>Sucrose</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Unopened pre-filled syringe </u></p><p>Store in a refrigerator (2&deg;C&ndash;8&deg;C). Do not freeze.</p><p>Keep the pre‑filled syringe in the outer carton in order to protect from light.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tremfya 200&nbsp;mg solution for injection in pre</u><u>‑filled syringe</u></p><p><u>&nbsp;</u></p><p>2&nbsp;mL solution in a pre‑filled glass syringe with a fixed needle and a needle shield, assembled in an automatic needle guard.</p><p>Tremfya is available in packs containing one pre‑filled syringe and in multipacks containing 2 (2&nbsp;packs of 1) pre-filled syringes.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tremfya 200&nbsp;mg solution for injection in pre</u><u>‑filled syringe</u><u> </u></p><p>&nbsp;</p><p>After removing the pre‑filled syringe from the refrigerator, keep the pre‑filled syringe inside the carton and allow to reach room temperature by waiting for 30&nbsp;minutes before injecting Tremfya. The pre‑filled syringe should not be shaken.</p><p>&nbsp;</p><p>Prior to use, a visual inspection of the pre‑filled syringe is recommended. The solution should be clear, colourless to light yellow, and may contain a few small white or clear particles. Tremfya should not be used if the solution is cloudy or discoloured, or contains large particles.</p><p>&nbsp;</p><p>Each pack is provided with an &lsquo;Instructions for use&rsquo; leaflet that fully describes the preparation and administration of the pre‑filled syringe.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Janssen Cilag International NV
Turnhoutseweg 30
B 2340 Beerse
Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                26-June-2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>